Science.gov

Sample records for drug tests

  1. Drug Testing. Research Brief

    ERIC Educational Resources Information Center

    Walker, Karen

    2007-01-01

    In 2002, the United States Supreme Court confirmed that in the school's role of in loco parentis, drug testing of students who were involved in athletics and extracurricular activities was constitutional. In a state of the union address, George W. Bush stated that drug testing in schools had been effective and was part of "our aggressive…

  2. Drug Testing. Research Brief

    ERIC Educational Resources Information Center

    Walker, Karen

    2005-01-01

    The Vernonia School District v. Acton Supreme Court decision in 1995, forever changed the landscape of the legality of drug testing in schools. This decision stated that students who were involved in athletic programs could be drug tested as long as the student's privacy was not invaded. According to some in the medical profession, there are two…

  3. Drug testing programs.

    PubMed

    Willette, R E

    1986-01-01

    Many Federal agencies and private companies are conducting drug tests on job applicants and employees. Although the reasons for testing and the circumstances under which testing is conducted vary considerably, the main intent of these programs is to provide a drug-free environment for other employees and a safe service to the public. The programs that have been most successful usually include a clear communication to all employees and applicants as to the nature of the drug program and the consequences of detected drug use. Also, successful programs usually afford employees some type of assistance and a second chance. Finally, it is essential for successful programs to provide a reasonable and fair approach that includes procedures for due process, that is, a line of review and appeal. PMID:3127722

  4. "Reasonable" Drug Testing.

    ERIC Educational Resources Information Center

    Dowling-Sendor, Benjamin

    2002-01-01

    Analysis of the U.S. Supreme Court's recent decision in "Board of Education of Independent School District No. 92 of Pottawatomie County v. Earls," wherein the Court held that random drug testing of students taking part in extracurricular activities is constitutional. (PKP)

  5. Drug testing in the neonate.

    PubMed

    Cotten, Steven W

    2012-09-01

    Drug testing in newborns comes with analytical, therapeutic, and legal issues, and interpretation of results may be left to physicians, nurses, or social services workers. The unique analytical and legal caveats pose a variety of challenges and therapeutic issues. Positive drug screening results can allow for proper medical management of withdrawal symptoms for certain drug classes. Legal implications and involvement of social services for assessment of child safety surround positive urine or meconium drug samples. Because laboratory results can potentially remove newborns from their biological parents, the caveats and limitations of drug testing in this population are of utmost importance. PMID:22939302

  6. Drug testing in oral fluid.

    PubMed

    Drummer, Olaf H

    2006-08-01

    Over the last decade there have been considerable developments in the use of oral fluid (saliva) for drug testing. Oral fluid can provide a quick and non-invasive specimen for drug testing. However, its collection may be thwarted by lack of available fluid due to a range of physiological factors, including drug use itself. Food and techniques designed to stimulate production of oral fluid can also affect the concentration of drugs. Current applications are mainly focused on drugs of abuse testing in employees at workplaces where drug use has safety implications, in drivers of vehicles at the roadside and in other situations where drug impairment is suspected. Testing has included alcohol (ethanol) and a range of clinical tests eg antibodies to HIV, therapeutic drugs and steroids. Its main application has been for testing for drugs of abuse such as the amphetamines, cocaine and metabolites, opioids such as morphine, methadone and heroin, and for cannabis. Oral fluid concentrations of basic drugs such as the amphetamines, cocaine and some opioids are similar or higher than those in plasma. Tetrahydrocannabinol (THC), the major species present from cannabis use, displays similar concentrations in oral fluid compared to blood in the elimination phase. However, there is significant local absorption of the drug in the oral cavity which increases the concentrations for a period after use of drug. Depot effects occur for other drugs introduced into the body that allow local absorption, such as smoking of tobacco (nicotine), cocaine, amphetamines, or use of sub-lingual buprenorphine. Screening techniques are usually an adaptation of those used in other specimens, with an emphasis on the parent drug since this is usually the dominant species present in oral fluid. Confirmatory techniques are largely based on mass spectrometry (MS) with an emphasis on Liquid Chromatography-Mass Spectrometry (LC-MS), due to low sample volumes and the low detection limits required. Drug testing

  7. The Drug-Testing Dilemma.

    ERIC Educational Resources Information Center

    Dowling-Sendor, Benjamin

    1999-01-01

    The recent decision of the 8th U.S. Circuit Court of Appeals in "Miller," based on the school district's interest in preventing possible abuse, gave legal support for random, suspiciousless drug testing of students. Contends this is a "slippery slope" argument, that the key factor in deciding whether to adopt a policy of random drug testing should…

  8. Implications of Drug Testing Cheerleaders

    ERIC Educational Resources Information Center

    Trachsler, Tracy A.; Birren, Genevieve

    2016-01-01

    With the untimely death of a University of Louisville cheerleader due to an accidental drug overdose in the summer of 2014, the athletic department representatives took steps to prevent future incidents by adding cheerleaders to the randomized drug testing protocols conducted at the university for the student-athletes involved in National…

  9. Drugs of Abuse Testing

    MedlinePlus

    ... WADA bans use of beta blockers in archery, golf, shooting, freestyle skiing, and snowboarding because they decrease ... pain medications. ^ Back to top Proudly sponsored by ... Learn more about ... Understanding Your Tests Inside the Lab ...

  10. Who Tests which Athletes for What Drugs?

    ERIC Educational Resources Information Center

    Gall, Sarah L.; And Others

    1988-01-01

    This article reviews trends in sports organizations' drug testing policies and procedures for its members, including which drugs are tested, who gets tested within the organizations, when tests are conducted, and penalties for those who test positive. (CB)

  11. Objective Testing: Urine and Other Drug Tests.

    PubMed

    Hadland, Scott E; Levy, Sharon

    2016-07-01

    Drug testing, when carefully collected and thoughtfully interpreted, offers a critical adjunct to clinical care and substance use treatment. However, because test results can be misleading if not interpreted in the correct clinical context, clinicians should always conduct a careful interview with adolescent patients to understand what testing is likely to show and then use testing to validate or refute their expectations. Because of the ease with which samples can be tampered, providers should also carefully reflect on their own collection protocols and sample validation procedures to ensure optimal accuracy." PMID:27338974

  12. Drug efficacy testing in mice.

    PubMed

    Kim, William Y; Sharpless, Norman E

    2012-01-01

    The traditional path of drug development passes from in vitro screening and response assessment to validation of drug efficacy in cell line xenografts. While xenografts have their merits, historically, more often than not, they have not served as an accurate predictor of drug efficacy in humans. The refinement and increased availability of genetically engineered mouse models (GEMMs) of cancer has made GEMMs an attractive avenue for the preclinical testing of therapeutic agents. The histopathologic and genetic resemblance of GEMMs to human cancer are an important measure to evaluate their suitability for pre-clinical studies and a number of studies using kinase inhibitors have now been performed in GEMMs. We have highlighted several of the salient advantages and challenges associated with GEMM studies. Well-characterized GEM models of human cancer should aide in the prioritization of both established and novel therapeutics. PMID:21823029

  13. 49 CFR 655.21 - Drug testing.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 7 2010-10-01 2010-10-01 false Drug testing. 655.21 Section 655.21 Transportation... TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Prohibited Drug Use § 655.21 Drug testing. (a) An employer shall establish a program that provides testing for...

  14. 49 CFR 655.21 - Drug testing.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 7 2011-10-01 2011-10-01 false Drug testing. 655.21 Section 655.21 Transportation... TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Prohibited Drug Use § 655.21 Drug testing. (a) An employer shall establish a program that provides testing for...

  15. 49 CFR 655.21 - Drug testing.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 7 2013-10-01 2013-10-01 false Drug testing. 655.21 Section 655.21 Transportation... TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Prohibited Drug Use § 655.21 Drug testing. (a) An employer shall establish a program that provides testing for...

  16. 49 CFR 655.21 - Drug testing.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 49 Transportation 7 2012-10-01 2012-10-01 false Drug testing. 655.21 Section 655.21 Transportation... TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Prohibited Drug Use § 655.21 Drug testing. (a) An employer shall establish a program that provides testing for...

  17. 49 CFR 655.21 - Drug testing.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 7 2014-10-01 2014-10-01 false Drug testing. 655.21 Section 655.21 Transportation... TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Prohibited Drug Use § 655.21 Drug testing. (a) An employer shall establish a program that provides testing for...

  18. 78 FR 22209 - Additional Synthetic Drug Testing

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-04-15

    ... COMMISSION 10 CFR Part 26 Additional Synthetic Drug Testing AGENCY: Nuclear Regulatory Commission. ACTION... NRC amend its Fitness for Duty program regulations to amend drug testing requirements to test for additional synthetic drugs currently not included in the regulations. The NRC determined that the...

  19. Workplace drug testing, different matrices different objectives.

    PubMed

    Tsanaclis, Lolita M; Wicks, John F C; Chasin, Alice A M

    2012-02-01

    Drug testing is used by employers to detect drug use by employees or job candidates. It can identify recent use of alcohol, prescription drugs, and illicit drugs as a screening tool for potential health and safety and performance issues. Urine is the most commonly used sample for illicit drugs. It detects the use of a drug within the last few days and as such is evidence of recent use; but a positive test does not necessarily mean that the individual was impaired at the time of the test. Abstention from use for three days will often produce a negative test result. Analysis of hair provides a much longer window of detection, typically 1 to 3 months. Hence the likelihood of a falsely negative test using hair is very much less than with a urine test. Conversely, a negative hair test is a substantially stronger indicator of a non-drug user than a negative urine test. Oral fluid (saliva) is also easy to collect. Drugs remain in oral fluid for a similar time as in blood. The method is a good way of detecting current use and is more likely to reflect current impairment. It offers promise as a test in post-accident, for cause, and on-duty situations. Studies have shown that within the same industrial settings, hair testing can detect twice as many drug users as urine testing. PMID:22362574

  20. A Model for Random Student Drug Testing

    ERIC Educational Resources Information Center

    Nelson, Judith A.; Rose, Nancy L.; Lutz, Danielle

    2011-01-01

    The purpose of this case study was to examine random student drug testing in one school district relevant to: (a) the perceptions of students participating in competitive extracurricular activities regarding drug use and abuse; (b) the attitudes and perceptions of parents, school staff, and community members regarding student drug involvement; (c)…

  1. Medicines and drug testing in the workplace.

    PubMed

    DuPont, R L

    1990-01-01

    Drug testing at work is rapidly becoming the standard in the United States. For drug testing to fulfill its promise as a vital part of the effort to end the drug abuse epidemic, it is essential that the tests be reliable so that people who are not using drugs are not falsely accused and that legitimate medical use of controlled substances not expose employees to harassment or labeling as drug abusers. To merit employee confidence, workplace drug testing needs to be made part of a program that includes these basic elements: (1) a clear and comprehensive policy; (2) secure collection; (3) chain-of-custody procedures; (4) retained positive samples; (5) an initial screening test; (6) a sophisticated confirmatory test; (7) a medical review officer; (8) a retest of retained positive samples in disputed cases; and (9) a system of quality control. In addition, this drug testing program needs to be built on a solid foundation that distinguishes between legitimate use of prescribed medicines and nonmedical drug use. This differentiation is the primary responsibility of the medical review officer. PMID:2096190

  2. [Workplace testing of drugs of abuse and psychotropic drugs].

    PubMed

    Mura, P; Saussereau, E; Brunet, B; Goullé, J-P

    2012-05-01

    In France, workplace testing of drugs of abuse and psychotropic drugs is rarely performed; meanwhile it is a major public health problem. Furthermore, France is the European country that has been associated with the highest increase of the use of drugs of abuse, particularly cannabis. So workplace biological screening of drugs of abuse and of psychotropic drugs exposure is of major concern. New analytical techniques have been developed during the last years. The authors will consider analytical screening of drugs of abuse and particularly the comparison of analytical techniques applied to urine and saliva. The advantages and the disadvantages of these two matrices will be considered. Urinary and blood quantification will be reviewed, but also the interest of hair testing to explore chronic exposure. The research of psychotropic drugs in biological fluids is also a part of this paper. New analytical trends are promising and complete analysis of these substances will be soon routinely possible in blood using a single spot test. PMID:22655580

  3. Prisoner subjects and drug testing.

    PubMed

    Lasagna, L

    1977-09-01

    Objections to prison research are based more often on opposition to the evils of prison life than to unethical practices and to the memories of atrocities committed in the name of science in Nazi prison camps during World War II. The National Commission's pronouncements on prison research specifically illustrate this general phenomenon. Having decided that research on prisoners can be performed ethically, and having learned that most prisoner volunteers bitterly resent being deprived of the opportunity to participate in research, the Commission has nevertheless stipulated prison conditions that cannot realistically be met and thus has de facto eliminated such research. The most serious potential loss is the elimination of the unique facility in Lexington, Kentucky--the Addiction Research Center. Predicting the addiction liability of drugs is not likely to be feasible in any nonprison setting, so that the addiction potential of new marketed drugs will be established in the future as it was in the past--by trial-and-error in patients, who will become the unwilling, uninformed research subjects in this area. PMID:892002

  4. Oral Fluid Testing for Drugs of Abuse

    PubMed Central

    Bosker, Wendy M.; Huestis, Marilyn A.

    2011-01-01

    BACKGROUND Oral fluid (OF) is an exciting alternative matrix for monitoring drugs of abuse in workplace, clinical toxicology, criminal justice, and driving under the influence of drugs (DUID) programs. During the last 5 years, scientific and technological advances in OF collection, point-of-collection testing devices, and screening and confirmation methods were achieved. Guidelines were proposed for workplace OF testing by the Substance Abuse and Mental Health Services Administration, DUID testing by the European Union’s Driving under the Influence of Drugs, Alcohol and Medicines (DRUID) program, and standardization of DUID research. Although OF testing is now commonplace in many monitoring programs, the greatest current limitation is the scarcity of controlled drug administration studies available to guide interpretation. CONTENT This review outlines OF testing advantages and limitations, and the progress in OF that has occurred during the last 5 years in collection, screening, confirmation, and interpretation of cannabinoids, opioids, amphetamines, cocaine, and benzodiazepines. We examine controlled drug administration studies, immunoassay and chromatographic methods, collection devices, point-of-collection testing device performance, and recent applications of OF testing. SUMMARY Substance Abuse and Mental Health Services Administration approval of OF testing was delayed because questions about drug OF disposition were not yet resolved, and collection device performance and testing assays required improvement. Here, we document the many advances achieved in the use of OF. Additional research is needed to identify new bio-markers, determine drug detection windows, characterize OF adulteration techniques, and evaluate analyte stability. Nevertheless, there is no doubt that OF offers multiple advantages as an alternative matrix for drug monitoring and has an important role in DUID, treatment, workplace, and criminal justice programs. PMID:19745062

  5. 49 CFR 199.107 - Drug testing laboratory.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 3 2011-10-01 2011-10-01 false Drug testing laboratory. 199.107 Section 199.107... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.107 Drug testing laboratory. (a) Each operator shall use for the drug testing required by...

  6. 49 CFR 199.107 - Drug testing laboratory.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 3 2010-10-01 2010-10-01 false Drug testing laboratory. 199.107 Section 199.107... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.107 Drug testing laboratory. (a) Each operator shall use for the drug testing required by...

  7. 49 CFR 199.107 - Drug testing laboratory.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 3 2013-10-01 2013-10-01 false Drug testing laboratory. 199.107 Section 199.107... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.107 Drug testing laboratory. (a) Each operator shall use for the drug testing required by...

  8. 49 CFR 199.107 - Drug testing laboratory.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 49 Transportation 3 2012-10-01 2012-10-01 false Drug testing laboratory. 199.107 Section 199.107... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.107 Drug testing laboratory. (a) Each operator shall use for the drug testing required by...

  9. 49 CFR 199.107 - Drug testing laboratory.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 3 2014-10-01 2014-10-01 false Drug testing laboratory. 199.107 Section 199.107... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.107 Drug testing laboratory. (a) Each operator shall use for the drug testing required by...

  10. Drug susceptibility testing of nontuberculous mycobacteria.

    PubMed

    van Ingen, Jakko; Kuijper, Ed J

    2014-01-01

    Diseases caused by nontuberculous mycobacteria are emerging in many settings. With an increased number of patients needing treatment, the role of drug susceptibility testing is again in the spotlight. This articles covers the history and methodology of drug susceptibility tests for nontuberculous mycobacteria, but focuses on the correlations between in vitro drug susceptibility, pharmacokinetics and in vivo outcomes of treatment. Among slow-growing nontuberculous mycobacteria, clear correlations have been established for macrolides and amikacin (Mycobacterium avium complex) and for rifampicin (Mycobacterium kansasii). Among rapid-growing mycobacteria, correlations have been established in extrapulmonary disease for aminoglycosides, cefoxitin and co-trimoxazole. In pulmonary disease, correlations are less clear and outcomes of treatment are generally poor, especially for Mycobacterium abscessus. The clinical significance of inducible resistance to macrolides among rapid growers is an important topic. The true role of drug susceptibility testing for nontuberculous mycobacteria still needs to be addressed, preferably within clinical trials. PMID:25340838

  11. Sports drug testing--an analyst's perspective.

    PubMed

    Trout, Graham J; Kazlauskas, Rymantas

    2004-01-10

    Sport plays a major role in the lives of many people, both for active participation and as entertainment. Sport is now a huge nationally and internationally based industry. The desire to win has led some athletes to resort to the use of performance enhancing drugs. With huge financial rewards now available in some sports the pressure to excel has grown. Some have argued that drug use should be given free rein, however most people are of the view that it is athletic prowess that should be applauded not the efficacy of various performance enhancing drugs. Apart from the obvious aspects of equality and fair play, the use of drugs is associated with significant health risks. In the 1960's the use of stimulants in sports such as cycling led to the death of at least one cyclist. Since 1968 the International Olympic Committee (IOC) has required all Olympic Games' host cities to provide laboratory facilities for the analysis and detection of performance enhancing drugs. There are now 29 IOC accredited laboratories throughout the world that routinely test samples from athletes for the presence of such drugs. The purpose of this tutorial review is to give an overview of drug testing procedures, including those that were used at the last summer Olympic Games in Sydney 2000, and the incorporation of the latest developments in analytical chemistry technology in the drug testing process. More recently, developments in biotechnology mean that the use of whole new classes of drugs are banned in sport, often requiring new methodologies and techniques for their analysis. The contest between those who wish to cheat and those who wish to maintain fair play in sport is an ongoing one. PMID:14737504

  12. Self-Reported Drug and Alcohol Use and Attitudes toward Drug Testing in High Schools with Random Student Drug Testing

    ERIC Educational Resources Information Center

    DuPont, Robert L.; Campbell, Michael D.; Campbell, Teresa G.; Shea, Corinne L.; DuPont, Helen S.

    2013-01-01

    Many schools implement random student drug testing (RSDT) programs as a drug prevention strategy. This study analyzes self-report surveys of students in eight secondary schools with well-established RSDT programs, comparing students who understood they were subject to testing and students who understood they were not subject to testing. Students…

  13. 21 CFR 343.90 - Dissolution and drug release testing.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 5 2012-04-01 2012-04-01 false Dissolution and drug release testing. 343.90 Section 343.90 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) DRUGS FOR HUMAN USE INTERNAL ANALGESIC, ANTIPYRETIC, AND ANTIRHEUMATIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures §...

  14. Respect versus Surveillance: Drug Testing Our Students

    ERIC Educational Resources Information Center

    Brendtro, Larry K.; Martin, Gordon A., Jr.

    2006-01-01

    This launches a new periodic feature in Reclaiming Children and Youth. "Justice Alerts" examines current laws and policies against the twofold standards of solid science and moral values. This inaugural article explores the legal issues and political rhetoric surrounding random drug testing in schools and describes how science is being skewed to…

  15. Why We Test Students for Drugs

    ERIC Educational Resources Information Center

    Brady, Lisa A.

    2008-01-01

    With 10 years of experience leading schools through random drug testing programs, the author, a superintendent, is convinced she's on the right track. At Hunterdon Central Regional High School District in Flemington, New Jersey, a school where she works as a superintendent, the author relates that they have seen a significant and well-documented…

  16. Does Drug Testing Deter Drug Court Participants from Using Drugs or Alcohol?

    ERIC Educational Resources Information Center

    Kleinpeter, Christine B.; Brocato, Jo; Koob, Jeffrey J.

    2010-01-01

    This study evaluates 3 drug-testing strategies implemented in 5 different jurisdictions with drug courts in Orange County, California. The purpose of the study was to determine whether the sweat patch acts as a deterrent and under what conditions it can be used to improve outcomes. Results indicated that although the use of the sweat patch did not…

  17. Ethical considerations in urine drug testing.

    PubMed

    Passik, Steven D; Kirsh, Kenneth L

    2011-01-01

    Recent passage of a House Bill in the state of Washington led to a commentary on whether mandates for urine drug testing of pain patients represented a breach of the Fourth and Fourteenth Amendment rights of patients. Issues over true consent to such tests and potential view of warrantless searches were discussed. The authors address these concerns in a broader context of risk management and stratification efforts, along with discussion about the need for a tailored approach in this arena and consideration of cost burden for such tests. Finally, the argument is made that social justice issues need to be considered (along with issues of autonomy, beneficence, and nonmaleficence). PMID:21810007

  18. 49 CFR 219.603 - Participation in drug testing.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false Participation in drug testing. 219.603 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Random Alcohol and Drug Testing Programs § 219.603 Participation in drug testing. A railroad shall, under the conditions specified in...

  19. Employee Drug Testing Policies in Police Departments. Research in Brief.

    ERIC Educational Resources Information Center

    McEwen, J. Thomas; And Others

    1986-01-01

    The development of drug testing policies and the implementation of drug testing procedures involve legal, ethical, medical, and labor relations issues. To learn how police departments are addressing the problem of drug use and drug testing of police officers, the National Institute of Justice sponsored a telephone survey of 33 major police…

  20. 49 CFR 219.603 - Participation in drug testing.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 4 2013-10-01 2013-10-01 false Participation in drug testing. 219.603 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Random Alcohol and Drug Testing Programs § 219.603 Participation in drug testing. A railroad shall, under the conditions specified in...

  1. 49 CFR 219.603 - Participation in drug testing.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 4 2014-10-01 2014-10-01 false Participation in drug testing. 219.603 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Random Alcohol and Drug Testing Programs § 219.603 Participation in drug testing. A railroad shall, under the conditions specified in...

  2. 10 CFR 707.8 - Applicant drug testing.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 4 2014-01-01 2014-01-01 false Applicant drug testing. 707.8 Section 707.8 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.8 Applicant drug testing. An applicant for a testing designated position will be tested for the use of illegal drugs...

  3. 10 CFR 707.8 - Applicant drug testing.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 4 2013-01-01 2013-01-01 false Applicant drug testing. 707.8 Section 707.8 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.8 Applicant drug testing. An applicant for a testing designated position will be tested for the use of illegal drugs...

  4. 10 CFR 707.8 - Applicant drug testing.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 4 2011-01-01 2011-01-01 false Applicant drug testing. 707.8 Section 707.8 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.8 Applicant drug testing. An applicant for a testing designated position will be tested for the use of illegal drugs...

  5. 10 CFR 707.8 - Applicant drug testing.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 4 2012-01-01 2012-01-01 false Applicant drug testing. 707.8 Section 707.8 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.8 Applicant drug testing. An applicant for a testing designated position will be tested for the use of illegal drugs...

  6. 10 CFR 707.8 - Applicant drug testing.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 4 2010-01-01 2010-01-01 false Applicant drug testing. 707.8 Section 707.8 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.8 Applicant drug testing. An applicant for a testing designated position will be tested for the use of illegal drugs...

  7. 76 FR 59574 - Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Federal Drug Testing...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-09-27

    ... Interim Final Rule (IFR) on September 27, 2010 [75 FR 59105] authorizing DOT-regulated employers to also... omission in the rule text of a final rule published on August 16, 2010 [75 FR ] 49850]. Specifically, we... Alcohol Testing Programs: Federal Drug Testing Custody and Control Form; Technical Amendment...

  8. Medication monitoring and drug testing ethics project.

    PubMed

    Payne, Richard; Moe, Jeffrey L; Sevier, Catherine Harvey; Sevier, David; Waitzkin, Michael

    2015-01-01

    In 2012, Duke University initiated a research project, funded by an unrestricted research grant from Millennium Laboratories, a drug testing company. The project focused on assessing the frequency and nature of questionable, unethical, and illegal business practices in the clinical drug testing industry and assessing the potential for establishing a business code of ethics. Laboratory leaders, clinicians, industry attorneys, ethicists, and consultants participated in the survey, were interviewed, and attended two face-to-face meetings to discuss a way forward. The study demonstrated broad acknowledgment of variations in the legal and regulatory environment, resulting in inconsistent enforcement of industry practices. Study participants expressed agreement that overtly illegal practices sometimes exist, particularly when laboratory representatives and clinicians discuss reimbursement, extent of testing, and potential business incentives with medical practitioners. Most respondents reported directly observing probable violations involving marketing materials, contracts, or, in the case of some individuals, directly soliciting people with offers of clinical supplies and other "freebies." While many study respondents were skeptical that voluntary standards alone would eliminate questionable business practices, most viewed ethics codes and credentialing as an important first step that could potentially mitigate uneven enforcement, while improving quality of care and facilitating preferred payment options for credentialed parties. Many were willing to participate in future discussions and industry-wide initiatives to improve the environment. PMID:25750169

  9. Toxicology and drug testing in aviation.

    PubMed

    Green, Kendall B

    2002-01-01

    The occupational physician working in the aviation industry must have some toxicological expertise. Airline production and maintenance operations, while similar to other large manufacturing facilities, use some exotic metals and composites with unique toxicity. Airport operations involve exposure of the ground crew to de-icing chemicals and jet fuels. Moreover, evaluation of drug test results requires a background in pharmacology, physiology, and laboratory methods. Frank response to employees and coordination of plans with industrial hygienists, managers, and employees are necessary when toxicological questions arise. This article also offers a Controversy (Substituted Urine: Offer a Retest or Not?). PMID:11872436

  10. To Test or Not to Test? Drug Testing Teachers: The View of the Superintendent

    ERIC Educational Resources Information Center

    DeMitchell, Todd A.; Kossakoski, Stephen; Baldasaro, Tony

    2008-01-01

    Purpose: School superintendents are charged with maintaining the safety and security of the schools in their district. One major recognized threat to the security and safety of students and staff is the use of illegal drugs. Superintendents are responding to the constitutionality of student drug-testing policies by implementing drug-testing…

  11. 10 CFR 707.10 - Drug testing for reasonable suspicion of illegal drug use.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 4 2012-01-01 2012-01-01 false Drug testing for reasonable suspicion of illegal drug use. 707.10 Section 707.10 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.10 Drug testing for reasonable suspicion of illegal drug use. (a)(1) It may be necessary...

  12. 10 CFR 707.10 - Drug testing for reasonable suspicion of illegal drug use.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 4 2014-01-01 2014-01-01 false Drug testing for reasonable suspicion of illegal drug use. 707.10 Section 707.10 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.10 Drug testing for reasonable suspicion of illegal drug use. (a)(1) It may be necessary...

  13. 10 CFR 707.10 - Drug testing for reasonable suspicion of illegal drug use.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 4 2011-01-01 2011-01-01 false Drug testing for reasonable suspicion of illegal drug use. 707.10 Section 707.10 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.10 Drug testing for reasonable suspicion of illegal drug use. (a)(1) It may be necessary...

  14. 10 CFR 707.10 - Drug testing for reasonable suspicion of illegal drug use.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 4 2013-01-01 2013-01-01 false Drug testing for reasonable suspicion of illegal drug use. 707.10 Section 707.10 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.10 Drug testing for reasonable suspicion of illegal drug use. (a)(1) It may be necessary...

  15. 10 CFR 707.10 - Drug testing for reasonable suspicion of illegal drug use.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 4 2010-01-01 2010-01-01 false Drug testing for reasonable suspicion of illegal drug use. 707.10 Section 707.10 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.10 Drug testing for reasonable suspicion of illegal drug use. (a)(1) It may be necessary...

  16. 49 CFR 655.41 - Pre-employment drug testing.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 7 2011-10-01 2011-10-01 false Pre-employment drug testing. 655.41 Section 655.41..., DEPARTMENT OF TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Types of Testing § 655.41 Pre-employment drug testing. (a)(1) Before allowing a covered employee...

  17. 76 FR 79204 - Random Drug Testing Rate for Covered Crewmembers

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-12-21

    ... SECURITY Coast Guard Random Drug Testing Rate for Covered Crewmembers AGENCY: Coast Guard, DHS. ACTION: Notice of minimum random drug testing rate. SUMMARY: The Coast Guard has set the calendar year 2012 minimum random drug testing rate at 50 percent of covered crewmembers. DATES: The minimum random...

  18. 49 CFR 219.501 - Pre-employment drug testing.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false Pre-employment drug testing. 219.501 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Pre-Employment Tests § 219.501 Pre-employment drug testing. (a) Prior to the first time a covered employee performs covered service for...

  19. 76 FR 1448 - Random Drug Testing Rate for Covered Crewmembers

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-01-10

    ... SECURITY Coast Guard Random Drug Testing Rate for Covered Crewmembers AGENCY: Coast Guard, DHS. ACTION: Notice of minimum random drug testing rate. SUMMARY: The Coast Guard has set the calendar year 2011 minimum random drug testing rate at 50 percent of covered crewmembers. DATES: The minimum random...

  20. 78 FR 4855 - Random Drug Testing Rate for Covered Crewmembers

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-01-23

    ... SECURITY Coast Guard Random Drug Testing Rate for Covered Crewmembers AGENCY: Coast Guard, DHS. ACTION: Notice of minimum random drug testing rate. SUMMARY: The Coast Guard has set the calendar year 2013 minimum random drug testing rate at 25 percent of covered crewmembers. The Coast Guard will continue...

  1. 14 CFR 120.117 - Implementing a drug testing program.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 14 Aeronautics and Space 3 2010-01-01 2010-01-01 false Implementing a drug testing program. 120.117 Section 120.117 Aeronautics and Space FEDERAL AVIATION ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) AIR CARRIERS AND OPERATORS FOR COMPENSATION OR HIRE: CERTIFICATION AND OPERATIONS DRUG AND ALCOHOL TESTING PROGRAM Drug Testing...

  2. 49 CFR 655.41 - Pre-employment drug testing.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 49 Transportation 7 2012-10-01 2012-10-01 false Pre-employment drug testing. 655.41 Section 655.41..., DEPARTMENT OF TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Types of Testing § 655.41 Pre-employment drug testing. (a)(1) Before allowing a covered employee...

  3. 49 CFR 655.41 - Pre-employment drug testing.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 7 2013-10-01 2013-10-01 false Pre-employment drug testing. 655.41 Section 655.41..., DEPARTMENT OF TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Types of Testing § 655.41 Pre-employment drug testing. (a)(1) Before allowing a covered employee...

  4. 49 CFR 219.501 - Pre-employment drug testing.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 4 2013-10-01 2013-10-01 false Pre-employment drug testing. 219.501 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Pre-Employment Tests § 219.501 Pre-employment drug testing. (a) Prior to the first time a covered employee performs covered service for...

  5. 49 CFR 655.41 - Pre-employment drug testing.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 7 2014-10-01 2014-10-01 false Pre-employment drug testing. 655.41 Section 655.41..., DEPARTMENT OF TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Types of Testing § 655.41 Pre-employment drug testing. (a)(1) Before allowing a covered employee...

  6. 49 CFR 219.501 - Pre-employment drug testing.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 4 2014-10-01 2014-10-01 false Pre-employment drug testing. 219.501 Section 219... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Pre-Employment Tests § 219.501 Pre-employment drug testing. (a) Prior to the first time a covered employee performs covered service for...

  7. 49 CFR 655.41 - Pre-employment drug testing.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 7 2010-10-01 2010-10-01 false Pre-employment drug testing. 655.41 Section 655.41..., DEPARTMENT OF TRANSPORTATION PREVENTION OF ALCOHOL MISUSE AND PROHIBITED DRUG USE IN TRANSIT OPERATIONS Types of Testing § 655.41 Pre-employment drug testing. (a)(1) Before allowing a covered employee...

  8. Drug test feasibility in a general population household survey.

    PubMed

    Fendrich, Michael; Johnson, Timothy P; Wislar, Joseph S; Hubbell, Amy

    2004-03-01

    Drug testing was used as an adjunct to a general population household drug use survey administered via audio computer assisted self-interview. Participants, ages 18-40 years residing in Chicago, were recruited to participate in three different biological tests (hair, oral fluid, and urine) presented in random order subsequent to completing an interview. Subjects had the option of participating in zero to three different tests. We examined participation/refusal in tests, reaction to testing requests, as well as variables associated with participation and reaction. Subjects were randomly assigned to a low (US$ 10 per test) or high (US$ 20 per test) incentive condition. Over 90% of the sample participated in at least one test, usually the oral fluid test. Associations between refusal status and two variables, socioeconomic status (SES) and presence of children in the household, provided partial support for the notion that drug test participation parallels the survey response process in general. Incentive level did not directly increase drug test participation. Reporting of recent illicit drug use was associated with participation in only one procedure, hair testing. Type of test offered and individual differences in willingness to be drug tested were important predictors of drug test refusal and subject reaction to testing requests. Compared with urine and hair testing, oral fluid testing had lower refusal rates and was generally more acceptable to respondents in a general population survey. The findings support the feasibility of incorporating multiple drug tests with modest incentives into general population household surveys on drug abuse. PMID:15036546

  9. Advances in anti-epileptic drug testing.

    PubMed

    Krasowski, Matthew D; McMillin, Gwendolyn A

    2014-09-25

    In the past twenty-one years, 17 new antiepileptic drugs have been approved for use in the United States and/or Europe. These drugs are clobazam, ezogabine (retigabine), eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide. Therapeutic drug monitoring is often used in the clinical dosing of the newer anti-epileptic drugs. The drugs with the best justifications for drug monitoring are lamotrigine, levetiracetam, oxcarbazepine, stiripentol, and zonisamide. Perampanel, stiripentol and tiagabine are strongly bound to serum proteins and are candidates for monitoring of the free drug fractions. Alternative specimens for therapeutic drug monitoring are saliva and dried blood spots. Therapeutic drug monitoring of the new antiepileptic drugs is discussed here for managing patients with epilepsy. PMID:24925169

  10. 21 CFR 862.3910 - Tricyclic antidepressant drugs test system.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 8 2011-04-01 2011-04-01 false Tricyclic antidepressant drugs test system. 862.3910 Section 862.3910 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  11. 21 CFR 862.3910 - Tricyclic antidepressant drugs test system.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 8 2010-04-01 2010-04-01 false Tricyclic antidepressant drugs test system. 862.3910 Section 862.3910 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  12. 21 CFR 862.3910 - Tricyclic antidepressant drugs test system.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 8 2013-04-01 2013-04-01 false Tricyclic antidepressant drugs test system. 862.3910 Section 862.3910 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  13. 21 CFR 862.3910 - Tricyclic antidepressant drugs test system.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 8 2012-04-01 2012-04-01 false Tricyclic antidepressant drugs test system. 862.3910 Section 862.3910 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  14. 21 CFR 862.3910 - Tricyclic antidepressant drugs test system.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 8 2014-04-01 2014-04-01 false Tricyclic antidepressant drugs test system. 862.3910 Section 862.3910 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  15. 75 FR 3153 - Drug and Alcohol Testing Program; Correction

    Federal Register 2010, 2011, 2012, 2013, 2014

    2010-01-20

    ..., 2009, we published a final rule (74 FR 22649) that amended the regulations governing FAA-required drug... TRANSPORTATION Federal Aviation Administration 14 CFR Parts 120 and 135 RIN 2120-AJ37 Drug and Alcohol Testing...: The Federal Aviation Administration (FAA) is correcting its drug and alcohol testing...

  16. What You Need To Know about Drug Testing in Schools.

    ERIC Educational Resources Information Center

    Office of National Drug Control Policy, Washington, DC.

    The Office of National Drug Control policy has put together this guide to assist educators, parents, and community leaders in determining whether student drug testing is appropriate for their schools. The aim is to provide anyone considering a drug-testing program in his or her community with a broad understanding of the issue and solid,…

  17. 49 CFR 199.105 - Drug tests required.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... directed by the substance abuse professional, to be performed in accordance with 49 CFR part 40. Follow-up... 49 Transportation 3 2010-10-01 2010-10-01 false Drug tests required. 199.105 Section 199.105... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug...

  18. 75 FR 9018 - Pipeline Safety: Random Drug Testing Rate

    Federal Register 2010, 2011, 2012, 2013, 2014

    2010-02-26

    ... percent for calendar year 2010. ] On January 19, 2010, PHMSA published an Advisory Bulletin (75 FR 2926... Pipeline and Hazardous Materials Safety Administration Pipeline Safety: Random Drug Testing Rate AGENCY... Percentage Rate for Random Drug Testing. SUMMARY: PHMSA has determined that the minimum random drug...

  19. 49 CFR 199.105 - Drug tests required.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... directed by the substance abuse professional, to be performed in accordance with 49 CFR part 40. Follow-up... 49 Transportation 3 2011-10-01 2011-10-01 false Drug tests required. 199.105 Section 199.105... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug...

  20. 49 CFR 199.105 - Drug tests required.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... directed by the substance abuse professional, to be performed in accordance with 49 CFR part 40. Follow-up... 49 Transportation 3 2013-10-01 2013-10-01 false Drug tests required. 199.105 Section 199.105... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug...

  1. 49 CFR 199.105 - Drug tests required.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... directed by the substance abuse professional, to be performed in accordance with 49 CFR part 40. Follow-up... 49 Transportation 3 2014-10-01 2014-10-01 false Drug tests required. 199.105 Section 199.105... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug...

  2. 14 CFR 120.35 - Testing for prohibited drugs.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 14 Aeronautics and Space 3 2014-01-01 2014-01-01 false Testing for prohibited drugs. 120.35... (CONTINUED) AIR CARRIERS AND OPERATORS FOR COMPENSATION OR HIRE: CERTIFICATION AND OPERATIONS DRUG AND... for prohibited drugs. (a) Each certificate holder or operator shall test each of its employees...

  3. 49 CFR 199.105 - Drug tests required.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... directed by the substance abuse professional, to be performed in accordance with 49 CFR part 40. Follow-up... 49 Transportation 3 2012-10-01 2012-10-01 false Drug tests required. 199.105 Section 199.105... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug...

  4. 14 CFR 120.35 - Testing for prohibited drugs.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 14 Aeronautics and Space 3 2012-01-01 2012-01-01 false Testing for prohibited drugs. 120.35... (CONTINUED) AIR CARRIERS AND OPERATORS FOR COMPENSATION OR HIRE: CERTIFICATION AND OPERATIONS DRUG AND... for prohibited drugs. (a) Each certificate holder or operator shall test each of its employees...

  5. 14 CFR 120.35 - Testing for prohibited drugs.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 14 Aeronautics and Space 3 2010-01-01 2010-01-01 false Testing for prohibited drugs. 120.35... (CONTINUED) AIR CARRIERS AND OPERATORS FOR COMPENSATION OR HIRE: CERTIFICATION AND OPERATIONS DRUG AND... for prohibited drugs. (a) Each certificate holder or operator shall test each of its employees...

  6. Scientific issues in drug testing: council on scientific affairs

    SciTech Connect

    Not Available

    1987-06-12

    Testing for drugs in biologic fluids, especially urine, is a practice that has become widespread. The technology of testing for drugs in urine has greatly improved in recent years. Inexpensive screening techniques are not sufficiently accurate for forensic testing standards, which must be met wihen a person's employment or reputation may be affected by results. This is particularly a concern during screening of a population in which the prevalence of drug use is very low, in which the predictive value of a positive result would be quite low. Physicians should be aware that results from drug testing can yield accurate evidence of prior exposure to drugs, but they do not provide information about patterns of drug use, about abuse of or dependence on drugs, or about mental or physical impairments that may result from drug use.

  7. 78 FR 37231 - Guidance for Industry; Guidance on Abbreviated New Drug Applications: Stability Testing of Drug...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-06-20

    ...The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance entitled ``ANDAs: Stability Testing of Drug Substances and Products.'' FDA is recommending generic drug manufacturers follow the stability testing recommendations in the International Conference on Harmonisation (ICH) guidances Q1A (R2) through Q1E. The use of these ICH recommendations will......

  8. 77 FR 58999 - Draft Guidance for Industry on Abbreviated New Drug Applications: Stability Testing of Drug...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-09-25

    ...The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled ``ANDAs: Stability Testing of Drug Substances and Products.'' FDA is recommending that generic drug manufacturers follow the stability testing recommendations in the International Conference on Harmonisation (ICH) guidances Q1A(R2) through Q1E. The use of these ICH recommendations......

  9. Special report. Drug testing in the workplace: an update.

    PubMed

    1994-10-01

    Workplace drug testing has become widespread in the U.S. and is a major component of the nation's "war on drugs." A recent annual survey by the American Management Association shows that the number of workplace drug-testing programs in surveyed companies grew almost 300% between 1987 and 1993. Nearly 85% of the 630 firms responding to the 1993 survey conduct some form of drug testing. Among activities sparking interest in drug testing are some highly publicized catastrophes in which drugs or alcohol played a major role--for example, the Exxon Valdez oil spill in Alaska which raised concern over threats to public safety. While the popularity of drug testing has increased, programs have been criticized at the same time for being inaccurate, costly, invasive of privacy, and even illegal in certain cases. As alternatives to urinalysis and other tests, companies have introduced impairment tests--also called performance tests and "fitness-for-duty" tests--which are computer-based and measure employees' eye-hand coordination or cognitive skills. Tests also have been introduced to detect drug residues on surfaces. In this report, we'll review some recent studies on drug testing and some of the programs currently being conducted. PMID:10137771

  10. Drug Testing in a University Athletic Program: Protocol and Implementation.

    ERIC Educational Resources Information Center

    Rovere, George D.; And Others

    1986-01-01

    An athletic drug education, counseling, and screening program at Wake Forest University is described. Decisions regarding which athletes to test, which drugs to test for and how to test for them, how to collect urine samples, and measures taken for a positive result are discussed. (MT)

  11. 21 CFR 864.3260 - OTC test sample collection systems for drugs of abuse testing.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 8 2012-04-01 2012-04-01 false OTC test sample collection systems for drugs of abuse testing. 864.3260 Section 864.3260 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES HEMATOLOGY AND PATHOLOGY DEVICES...

  12. 21 CFR 864.3260 - OTC test sample collection systems for drugs of abuse testing.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 8 2013-04-01 2013-04-01 false OTC test sample collection systems for drugs of abuse testing. 864.3260 Section 864.3260 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES HEMATOLOGY AND PATHOLOGY DEVICES...

  13. 21 CFR 864.3260 - OTC test sample collection systems for drugs of abuse testing.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 8 2014-04-01 2014-04-01 false OTC test sample collection systems for drugs of abuse testing. 864.3260 Section 864.3260 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES HEMATOLOGY AND PATHOLOGY DEVICES...

  14. 21 CFR 864.3260 - OTC test sample collection systems for drugs of abuse testing.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 8 2011-04-01 2011-04-01 false OTC test sample collection systems for drugs of abuse testing. 864.3260 Section 864.3260 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES HEMATOLOGY AND PATHOLOGY DEVICES...

  15. 21 CFR 864.3260 - OTC test sample collection systems for drugs of abuse testing.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 8 2010-04-01 2010-04-01 false OTC test sample collection systems for drugs of abuse testing. 864.3260 Section 864.3260 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES HEMATOLOGY AND PATHOLOGY DEVICES...

  16. 49 CFR 219.605 - Positive drug test results; procedures.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false Positive drug test results; procedures. 219.605 Section 219.605 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Random Alcohol and Drug...

  17. 49 CFR 40.85 - What drugs do laboratories test for?

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Drug Testing Laboratories § 40.85 What drugs do laboratories... test. You must not test “DOT specimens” for any other drugs. (a) Marijuana metabolites. (b)...

  18. 49 CFR 40.85 - What drugs do laboratories test for?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Drug Testing Laboratories § 40.85 What drugs do laboratories... test. You must not test “DOT specimens” for any other drugs. (a) Marijuana metabolites. (b)...

  19. 49 CFR 40.85 - What drugs do laboratories test for?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Drug Testing Laboratories § 40.85 What drugs do laboratories... test. You must not test “DOT specimens” for any other drugs. (a) Marijuana metabolites. (b)...

  20. 49 CFR 40.85 - What drugs do laboratories test for?

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Drug Testing Laboratories § 40.85 What drugs do laboratories... test. You must not test “DOT specimens” for any other drugs. (a) Marijuana metabolites. (b)...

  1. Virologic Tools for HCV Drug Resistance Testing

    PubMed Central

    Fourati, Slim; Pawlotsky, Jean-Michel

    2015-01-01

    Recent advances in molecular biology have led to the development of new antiviral drugs that target specific steps of the Hepatitis C Virus (HCV) lifecycle. These drugs, collectively termed direct-acting antivirals (DAAs), include non-structural (NS) HCV protein inhibitors, NS3/4A protease inhibitors, NS5B RNA-dependent RNA polymerase inhibitors (nucleotide analogues and non-nucleoside inhibitors), and NS5A inhibitors. Due to the high genetic variability of HCV, the outcome of DAA-based therapies may be altered by the selection of amino-acid substitutions located within the targeted proteins, which affect viral susceptibility to the administered compounds. At the drug developmental stage, preclinical and clinical characterization of HCV resistance to new drugs in development is mandatory. In the clinical setting, accurate diagnostic tools have become available to monitor drug resistance in patients who receive treatment with DAAs. In this review, we describe tools available to investigate drug resistance in preclinical studies, clinical trials and clinical practice. PMID:26690198

  2. Chemical dependency and drug testing in the workplace.

    PubMed Central

    Osterloh, J D; Becker, C E

    1990-01-01

    Urine testing for drug use in the workplace is now widespread, with the prevalence of positive drug tests in the work force being 0% to 15%. The prevalence of marijuana use is highest, and this can be reliably tested. Though it is prudent to rid the workplace of drug use, there is little scientific study on the relationship of drug use and workplace outcomes, such as productivity and safety. Probable-cause testing and preemployment testing are the most common applications. Random testing has been less accepted owing to its higher costs, unresolved legal issues, and predictably poor test reliability. Legal issues have focused on the right to policy, discrimination, and the lack of due process. The legal cornerstone of a good program is a policy that is planned and agreed on by both labor and management, which serves both as a contract and as a procedure in which expectations and consequences are known. The National Institute on Drug Abuse is certifying laboratories doing employee drug testing. Testing methods when done correctly are less prone to error than in the past, but screening tests can be defeated by adulterants. Although the incidence of false-positive results is low, such tests are less reliable when the prevalence of drug abuse is also low. PMID:2190418

  3. 77 FR 75896 - Alcohol and Drug Testing: Determination of Minimum Random Testing Rates for 2013

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-12-26

    ... Federal Railroad Administration 49 CFR Part 219 Alcohol and Drug Testing: Determination of Minimum Random.... According to data from FRA's Management Information System, the rail industry's random drug testing positive... (Administrator) has therefore determined that the minimum annual random drug testing rate for the period...

  4. 78 FR 41999 - Combined Drug and Alcohol Testing Programs

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-07-15

    ..., final rule titled ``Drug and Alcohol Testing Program'' (74 FR 22653). 3. It reorganizes existing rule... Proposed Rulemaking (NPRM) (77 FR 39194), entitled ``Combined Drug and Alcohol Testing Programs.'' The..., the National Air Tour Safety Standards rule (72 FR 6884, February 13, 2007) established a...

  5. 49 CFR 219.601 - Railroad random drug testing programs.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 4 2011-10-01 2011-10-01 false Railroad random drug testing programs. 219.601 Section 219.601 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD... Programs § 219.601 Railroad random drug testing programs. (a) Submission. Each railroad must submit for...

  6. 49 CFR 219.601 - Railroad random drug testing programs.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 4 2013-10-01 2013-10-01 false Railroad random drug testing programs. 219.601 Section 219.601 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD... Programs § 219.601 Railroad random drug testing programs. (a) Submission. Each railroad must submit for...

  7. 49 CFR 219.601 - Railroad random drug testing programs.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false Railroad random drug testing programs. 219.601 Section 219.601 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD... Programs § 219.601 Railroad random drug testing programs. (a) Submission. Each railroad must submit for...

  8. 49 CFR 219.601 - Railroad random drug testing programs.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 49 Transportation 4 2012-10-01 2012-10-01 false Railroad random drug testing programs. 219.601 Section 219.601 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD... Programs § 219.601 Railroad random drug testing programs. (a) Submission. Each railroad must submit for...

  9. 49 CFR 219.601 - Railroad random drug testing programs.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... 49 Transportation 4 2014-10-01 2014-10-01 false Railroad random drug testing programs. 219.601 Section 219.601 Transportation Other Regulations Relating to Transportation (Continued) FEDERAL RAILROAD... Programs § 219.601 Railroad random drug testing programs. (a) Submission. Each railroad must submit for...

  10. An Assessment of Drug Testing within the Construction Industry.

    ERIC Educational Resources Information Center

    Gerber, Jonathan K.; Yacoubian, George S., Jr.

    2002-01-01

    Investigates the efficacy of workplace drug-testing programs in reducing injury incident rates and workers' compensation experience-rating modification factors within the construction industry. Analyses indicate that companies with drug-testing programs experienced a 51 percent reduction in incident rates within two years of implementation.…

  11. Drug testing in the Australian workplace: overview of the issues.

    PubMed

    Blaze-Temple, D

    1992-01-01

    This paper is an overview of the issues surrounding employee drug testing programs as they apply to the Australian workplace. Drug testing may be seen within a historical context of control over workers. Its practice is most prevalent in the USA, but it is also occurring in Australia, Canada and England. It is undeniable that alcohol and other drug use causes significant problems in many workplaces, though the apparently substantial costs to industry and the prevalence of drug use among workers are difficult to estimate with any degree of precision. Drug testing programs in the workplace appear to have majority public support in the USA and are even supported by some unions in Australia and the USA; there are, however, critics of the programs. The evaluation evidence to date is sparse, but is promising in that it suggests that drug testing programs can be responsible for reducing the prevalence of drug use among workers as well as dramatically reducing company costs for absenteeism, accidents and medical insurance claims. However, due to methodological shortcomings one cannot state conclusively that drug testing programs are as effective as they appear to be. Research using more rigorous designs and generating data that can be compared across studies is needed. Distasteful though drug testing is, we may see benefits in its use, similar in concept to random breath testing on our roads. Many of the procedural and legal problems in early US programs have been eliminated, refinements which should assist Australians. The legal issues, however, are quite different in Australia. A drug testing program should not be the sole remedy for reducing alcohol and other drug problems in the workplace and such a program must also be accompanied by rehabilitation and educational components. Ethical issues are briefly discussed. PMID:16840069

  12. Why We Test Students for Drugs

    ERIC Educational Resources Information Center

    Brady, Lisa A.

    2008-01-01

    Today, there is a collective national awareness that an unacceptable number of teens are involved in the use of dangerous drugs such as methamphetamine, ecstasy, and heroin, and they have access to high-grade marijuana. Alcohol use, even more pervasive, results in risky sexual behaviors, automobile accidents, and even death. To the dismay of many…

  13. Interpretation of Oral Fluid Tests for Drugs of Abuse

    PubMed Central

    CONE, EDWARD J.; HUESTIS, MARILYN A.

    2009-01-01

    Oral fluid testing for drugs of abuse offers significant advantages over urine as a test matrix. Collection can be performed under direct observation with reduced risk of adulteration and substitution. Drugs generally appear in oral fluid by passive diffusion from blood, but also may be deposited in the oral cavity during oral, smoked, and intranasal administration. Drug metabolites also can be detected in oral fluid. Unlike urine testing, there may be a close correspondence between drug and metabolite concentrations in oral fluid and in blood. Interpretation of oral fluid results for drugs of abuse should be an iterative process whereby one considers the test results in the context of program requirements and a broad scientific knowledge of the many factors involved in determining test outcome. This review delineates many of the chemical and metabolic processes involved in the disposition of drugs and metabolites in oral fluid that are important to the appropriate interpretation of oral fluid tests. Chemical, metabolic, kinetic, and analytic parameters are summarized for selected drugs of abuse, and general guidelines are offered for understanding the significance of oral fluid tests. PMID:17332074

  14. Adverse Outcome Pathways and Drug-Induced Liver Injury Testing.

    PubMed

    Vinken, Mathieu

    2015-07-20

    Drug-induced liver injury is a prominent reason for premarketing and postmarketing drug withdrawal and can be manifested in a number of ways, such as cholestasis, steatosis, and fibrosis. The mechanisms driving these toxicological processes have been well characterized and have been emdedded in adverse outcome pathway frameworks in recent years. This review evaluates these constructs and simultaneously illustrates their use in the preclinical testing of drug-induced liver injury. PMID:26119269

  15. Adverse outcome pathways and drug-induced liver injury testing

    PubMed Central

    Vinken, Mathieu

    2015-01-01

    Drug-induced liver injury is a prominent reason for premarketing and postmarketing drug withdrawal and can be manifested in a number of ways, such as cholestasis, steatosis and fibrosis. The mechanisms driving these toxicological processes have been well characterized and have been emdedded in adverse outcome pathway frameworks in recent years. This paper reviews these constructs and simultaneously illustrates their use in the preclinical testing of drug-induced liver injury. PMID:26119269

  16. Fluorescence And Alternative Methods In Urine Drug Testing

    NASA Astrophysics Data System (ADS)

    Jain, Naresh C.

    1988-04-01

    Drug abuse has become-one of the most compelling realities _ ot contemporary society. It has penetrated every segment ot our population: trom schools to sports and trom organized crime to board rooms . Drugs in tie w9rkplace allegedly cost government agencies and business millions ot dollars each year in increased absenteeism,. poor work performance, thefts,accidents andwastedtime. The President's Commission on Organized Crime and the federal government are in tavor ot urine drug testing. In fact many employers are now resorting to urine drug testing on current and prospective employees. This presep.tation discusses different laboratory methods used in urine drug.testing, including immunoassays, fluorescence polarization, thin layer chromatography, high pressure liquid chromatography, gas chromatography and gas-chromatography-mass spectrometry.

  17. Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance

    PubMed Central

    Shafer, Robert W.

    2002-01-01

    There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse transcriptase (RT) inhibitors, and nonnucleoside RT inhibitors. HIV-1 resistance to these drugs is caused by mutations in the protease and RT enzymes, the molecular targets of these drugs. Drug resistance mutations arise most often in treated individuals, resulting from selective drug pressure in the presence of incompletely suppressed virus replication. HIV-1 isolates with drug resistance mutations, however, may also be transmitted to newly infected individuals. Three expert panels have recommended that HIV-1 protease and RT susceptibility testing should be used to help select HIV drug therapy. Although genotypic testing is more complex than typical antimicrobial susceptibility tests, there is a rich literature supporting the prognostic value of HIV-1 protease and RT mutations. This review describes the genetic mechanisms of HIV-1 drug resistance and summarizes published data linking individual RT and protease mutations to in vitro and in vivo resistance to the currently available HIV drugs. PMID:11932232

  18. Creating and evaluating genetic tests predictive of drug response

    PubMed Central

    Weiss, Scott T.; McLeod, Howard L.; Flockhart, David A.; Dolan, M. Eileen; Benowitz, Neal L.; Johnson, Julie A.; Ratain, Mark J.; Giacomini, Kathleen M.

    2009-01-01

    A key goal of pharmacogenetics — the use of genetic variation to elucidate inter-individual variation in drug treatment response — is to aid the development of predictive genetic tests that could maximize drug efficacy and minimize drug toxicity. The completion of the Human Genome Project and the associated HapMap Project, together with advances in technologies for investigating genetic variation, have greatly advanced the potential to develop such tests; however, many challenges remain. With the aim of helping to address some of these challenges, this article discusses the steps that are involved in the development of predictive tests for drug treatment response based on genetic variation, and factors that influence the development and performance of these tests. PMID:18587383

  19. Perceptions of Genetic Testing and Genomic Medicine among Drug Users

    PubMed Central

    Perlman, David C.; Gelpí-Acosta, Camila; Friedman, Samuel R.; Jordan, Ashly E.; Hagan, Holly

    2014-01-01

    Background Genetic testing will soon enter care for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), and for addiction. There is a paucity of data on how to disseminate genetic testing into healthcare for marginalized populations. We explored drug users’ perceptions of genetic testing. Methods Six focus groups were conducted with 34 drug users recruited from syringe exchange programs and an HIV clinic between May and June 2012. Individual interviews were conducted with participants reporting previous genetic testing. Results All participants expressed acceptance of genetic testing to improve care, but most had concerns regarding confidentiality and implications for law enforcement. Most expressed more comfort with genetic testing based on individual considerations rather than testing based on race/ethnicity. Participants expressed comfort with genetic testing in medical care rather than drug treatment settings and when specifically asked permission, with peer support, and given a clear rationale. Conclusions Although participants understood the potential value of genetic testing, concerns regarding breaches in confidentiality and discrimination may reduce testing willingness. Safeguards against these risks, peer support, and testing in medical settings based on individual factors and with clear rationales provided may be critical in efforts to promote acceptance of genetic testing among drug users. PMID:25037119

  20. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria.

    PubMed

    van Ingen, Jakko; Boeree, Martin J; van Soolingen, Dick; Mouton, Johan W

    2012-06-01

    Nontuberculous mycobacteria (NTM) are increasingly recognized as causative agents of opportunistic infections in humans. For most NTM infections the therapy of choice is drug treatment, but treatment regimens differ by species, in particular between slow (e.g. Mycobacterium avium complex, Mycobacterium kansasii) and rapid growers (e.g. Mycobacterium abscessus, Mycobacterium fortuitum). In general, drug treatment is long, costly, and often associated with drug-related toxicities; outcome of drug treatment is poor and is likely related to the high levels of natural antibiotic resistance in NTM. The role of drug susceptibility testing (DST) in the choice of agents for antimicrobial treatment of NTM disease, mainly that by slow growers, remains subject of debate. There are important discrepancies between drug susceptibility measured in vitro and the activity of the drug observed in vivo. In part, these discrepancies derive from laboratory technical issues. There is still no consensus on a standardized method. With the increasing clinical importance of NTM disease, DST of NTM is again in the spotlight. This review provides a comprehensive overview of the mechanisms of drug resistance in NTM, phenotypic methods for testing susceptibility in past and current use for DST of NTM, as well as molecular approaches to assess drug resistance. PMID:22525524

  1. Drug Testing in Schools: Policies, Practices, and Association with Student Drug Use. YES Occasional Papers. Paper 2

    ERIC Educational Resources Information Center

    Yamaguchi, Ryoko; Johnston, Lloyd D.; O'Malley, Patrick M.

    2003-01-01

    Despite considerable recent public and judicial attention to the issue of drug testing, little empirical research has focused on the relationship between drug testing in schools and the actual use of illicit drugs by students. To explore this issue, we use school-level survey data about drug testing from the Youth, Education, and Society study and…

  2. 49 CFR 199.103 - Use of persons who fail or refuse a drug test.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 3 2010-10-01 2010-10-01 false Use of persons who fail or refuse a drug test. 199... SAFETY DRUG AND ALCOHOL TESTING Drug Testing § 199.103 Use of persons who fail or refuse a drug test. (a... successfully completed required education or treatment; and (3) Not failed a drug test required by this...

  3. Detection and prevalence of drug use in arrested drivers using the Dräger Drug Test 5000 and Affiniton DrugWipe oral fluid drug screening devices.

    PubMed

    Logan, Barry K; Mohr, Amanda L A; Talpins, Stephen K

    2014-09-01

    The use of oral fluid (OF) drug testing devices offers the ability to rapidly obtain a drug screening result at the time of a traffic stop. We describe an evaluation of two such devices, the Dräger Drug Test 5000 and the Affiniton DrugWipe, to detect drug use in a cohort of drivers arrested from an investigation of drug impaired driving (n = 92). Overall, 41% of these drivers were ultimately confirmed positive by mass spectrometry for the presence of one or more drugs. The most frequently detected drugs were cannabinoids (30%), benzodiazepines (11%) and cocaine (10%). Thirty-nine percent of drivers with blood alcohol concentrations >0.08 g/100 mL were found to be drug positive. Field test results obtained from OF samples were compared with collected OF and urine samples subsequently analyzed in the laboratory by gas or liquid chromatography-mass spectrometry. The Dräger Drug Test 5000 (DDT5000) and DrugWipe returned overall sensitivities of 51 and 53%, and positive predictive values of 93 and 63%, respectively. The most notable difference in performance was the DDT5000's better sensitivity in detecting marijuana use. Both devices failed to detect benzodiazepine use. Oral fluid proved to be a more effective confirmatory specimen, with more drugs being confirmed in OF than urine. PMID:24894458

  4. LC-MS: a powerful tool in workplace drug testing.

    PubMed

    Gallardo, E; Barroso, M; Queiroz, J A

    2009-03-01

    Workplace drug testing is a well-established application of forensic toxicology and it aims to reduce workplace accidents caused by affected workers. Several classes of abused substances may be involved, such as alcohol, amphetamines, cannabis, cocaine, opiates and also prescription drugs, such as benzodiazepines. The use of alternative biological specimens such as hair, oral fluid or sweat in workplace drug testing presents several advantages over urinalysis-mainly the fact that sample collection can be performed easily without infringing on the examinee's privacy, so the subject is more likely to perform the test. However, drugs are usually present in these alternative specimens at low concentrations and the amount of sample available for analysis is small. The use of highly sensitive techniques is therefore necessary. In fact, the successful interface of liquid chromatography with mass spectrometry (LC-MS) has brought a new light into bioanalytical and forensic sciences as it allows the detection of drugs and metabolites at concentrations that are difficult to analyse using the more commonly adopted GC-MS based techniques. This paper will discuss the importance of LC-MS in supporting workplace drug-testing programmes. The combination of LC-MS with innovative instrumentation such as triple quadrupoles, ion traps and time-of-flight mass spectrometers will also be focused. PMID:20355182

  5. Pharmacogenomic Testing for Neuropsychiatric Drugs: Current Status of Drug Labeling, Guidelines for Using Genetic Information, and Test Options

    PubMed Central

    Drozda, Katarzyna; Müller, Daniel J.; Bishop, Jeffrey R.

    2014-01-01

    Advancements in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice. Understanding how and when to use this technology to help guide pharmacotherapy used to treat neuropsychiatric conditions remains a challenge for many clinicians. Currently, guidelines exist to assist clinicians in the use of genetic information for drug selection and/or dosing for the tricyclic antidepressants, carbamazepine, and phenytoin. Additional language in the product labeling suggests that genetic information may also be useful for assessing the starting and target doses, as well as drug interaction potential, for a number of other medications used to treat psychiatric and neurological conditions. In this review, we outline the current status of pharmacogenomic testing for neuropsychiatric drugs as it pertains to information contained in drug labeling, consensus guidelines, and test panels, as well as considerations related to obtaining tests for patients. PMID:24523097

  6. 14 CFR 120.109 - Types of drug testing required.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... CFR part 40). (a) Pre-employment drug testing. (1) No employer may hire any individual for a safety... the employer's Substance Abuse Professional conducted in accordance with the provisions of 49 CFR part... accordance with the provisions of 49 CFR part 40. (4) Follow-up testing shall not exceed 60 months after...

  7. 14 CFR 120.109 - Types of drug testing required.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... CFR part 40). (a) Pre-employment drug testing. (1) No employer may hire any individual for a safety... the employer's Substance Abuse Professional conducted in accordance with the provisions of 49 CFR part... accordance with the provisions of 49 CFR part 40. (4) Follow-up testing shall not exceed 60 months after...

  8. 14 CFR 120.109 - Types of drug testing required.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... CFR part 40). (a) Pre-employment drug testing. (1) No employer may hire any individual for a safety... the employer's Substance Abuse Professional conducted in accordance with the provisions of 49 CFR part... accordance with the provisions of 49 CFR part 40. (4) Follow-up testing shall not exceed 60 months after...

  9. 14 CFR 120.109 - Types of drug testing required.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... CFR part 40). (a) Pre-employment drug testing. (1) No employer may hire any individual for a safety... the employer's Substance Abuse Professional conducted in accordance with the provisions of 49 CFR part... accordance with the provisions of 49 CFR part 40. (4) Follow-up testing shall not exceed 60 months after...

  10. 14 CFR 120.109 - Types of drug testing required.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... CFR part 40). (a) Pre-employment drug testing. (1) No employer may hire any individual for a safety... the employer's Substance Abuse Professional conducted in accordance with the provisions of 49 CFR part... accordance with the provisions of 49 CFR part 40. (4) Follow-up testing shall not exceed 60 months after...

  11. 49 CFR 219.701 - Standards for drug and alcohol testing.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false Standards for drug and alcohol testing. 219.701... ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Drug and Alcohol Testing Procedures § 219.701 Standards for drug and alcohol testing. (a) Drug testing required or authorized by subparts...

  12. Current developments in drug testing in oral fluid.

    PubMed

    Pil, Kristof; Verstraete, Alain

    2008-04-01

    In the last few years, significant developments have occurred on the key issues involved in oral fluid drug testing. New pharmacokinetic studies have been conducted, optimal cutoffs have been proposed, and new studies have examined the correlation between oral fluid drug concentrations and impairment. Recent studies (eg, the discovery of the presence of THC-COOH in oral fluid) can contribute to solve the issue of false-positive results caused by passive exposure to marijuana. Reliable point-of-care drug testing is still problematic, especially for cannabinoids and benzodiazepines. To date, there is no device that allows both reliable and practical point-of-care testing. The importance of liquid chromatography- tandem mass spectrometry in confirmation analysis has increased over the last several years. It can be expected that this trend will continue because the low sample volumes make simultaneous detection of different drug classes with limited sample preparation necessary. Literature on proficiency testing to ensure reliability and comparability of results is limited. Oral fluid has become an important sample type in driving under the influence research, and the first legal random drug testing program in oral fluid since 2004 has been organized in Victoria. It can be expected that the role of oral fluid as an alternative matrix will keep increasing in the future. PMID:18367980

  13. 78 FR 78275 - Alcohol and Drug Testing: Determination of Minimum Random Testing Rates for 2014

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-12-26

    ...According to data from FRA's Management Information System, the rail industry's random drug testing positive rate has remained below 1.0 percent for the last two years. FRA's Administrator has therefore determined that the minimum annual random drug testing rate for the period January 1, 2014, through December 31, 2014, will remain at 25 percent of covered railroad employees. In addition,......

  14. 76 FR 80781 - Alcohol and Drug Testing: Determination of Minimum Random Testing Rates for 2012

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-12-27

    ... Minimum Random Testing Rates for 2012 AGENCY: Federal Railroad Administration (FRA), DOT. ACTION: Notice... random drug testing ] positive rate has remained below 1.0 percent for the last two years. The Federal Railroad Administrator (Administrator) has therefore determined that the minimum annual random drug...

  15. Random Student Drug Testing as a School-Based Drug Prevention Strategy

    PubMed Central

    DuPont, Robert L.; Merlo, Lisa J.; Arria, Amelia M.; Shea, Corinne L.

    2012-01-01

    Aim This article describes the goals and current practice of school-based random student drug testing (RSDT) as part of an overall drug prevention strategy, briefly explores the available literature evaluating its effectiveness, and discusses the controversies related to RSDT. Method Authors describe the rationale for RSDT programs and the prevalence of RSDT and other drug testing programs in schools. Eight major criticisms and controversies in RSDT are discussed including those related to acceptance of RSDT, program effectiveness, costs, legality, and effects of drug testing on students. The limitations of the current literature are explored. Findings Although there is limited empirical evidence to support or refute the efficacy of RSDT in schools, there remains substantial opposition to such programs, which may contribute to the paucity of empirical studies of RSDT. Conclusions Rigorous long-term evaluations are needed to evaluate the effectiveness of various versions of RSDT programs to prevent drug use and identify students in need of assistance to become and stay drug-free. PMID:22906236

  16. Adulterants causing false negatives in illicit drug testing.

    PubMed

    Mikkelsen, S L; Ash, K O

    1988-11-01

    Illicit-drug users may attempt to falsify results by in vitro adulteration of specimens. We investigated eight additives (NaCl, Visine, handsoap, Drano, bleach, vinegar, golden-seal tea, and lemon juice) claimed by drug users to invalidate enzyme immunoassay (EIA) drug assays. We also analyzed adulterated urine specimens to determine if they could be identified, adding adulterants at several concentrations to 222 EIA-positive specimens confirmed by gas chromatography and mass spectrometry (GC/MS) to contain illicit drugs. To identify adulterated urines, we monitored pH, relative density, and urine color and turbidity at adulterant concentrations that falsified EIA results. Specimens contaminated with NaCl had relative densities greater than 1.035. Liquid Drano, bleach, and vinegar shifted urine pH outside the physiological range. Golden-seal tea caused a dark appearance, and specimens containing liquid soap were unusually cloudy. Lemon juice had no effect on the assays. Visine was the only adulterant not detected. The adulterants interfered somewhat differently with each of the drug assays. EIA assays for illicit drugs can be invalidated by specimen adulteration producing false-negative results. Therefore, if urine drug testing is to be conducted, pH, relative density, and appearance should be assessed and suspect specimens should be rejected. Not all adulterants can be detected, so observed collection is strongly recommended. PMID:3052928

  17. 49 CFR 40.85 - What drugs do laboratories test for?

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... 49 Transportation 1 2012-10-01 2012-10-01 false What drugs do laboratories test for? 40.85 Section 40.85 Transportation Office of the Secretary of Transportation PROCEDURES FOR TRANSPORTATION WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Drug Testing Laboratories § 40.85 What drugs do laboratories test for? As a laboratory, you must test for...

  18. In vitro pyrogen test for toxic or immunomodulatory drugs.

    PubMed

    Daneshian, Mardas; Guenther, Armin; Wendel, Albrecht; Hartung, Thomas; von Aulock, Sonja

    2006-06-30

    Pyrogenic contaminations of some classes of injectable drugs, e.g. toxic or immunomodulatory as well as false-positive drugs, represent a major risk which cannot yet be excluded due to the limitations of current tests. Here we describe a modification of the In vitro Pyrogen Test termed AWIPT (Adsorb, Wash, In vitro Pyrogen Test), which addresses this problem by introducing a pre-incubation step in which pyrogenic contaminations in the test sample are adsorbed to albumin-coated beads. After rinsing, the beads are incubated with human whole blood and the release of the endogenous pyrogen interleukin-1beta is measured as a marker of pyrogenic activity. Intentional contaminations with lipopolysaccharide were retrieved from the chemotherapeutic agents paclitaxel, cisplatin and liposomal daunorubicin, the antibiotic gentamicin, the antifungal agent liposomal amphotericin B, and the corticosteroid prednisolone at lower dilutions than in the standard in vitro pyrogen test. This represents a promising new approach for the detection of pyrogenic contamination in drugs or in drugs containing interfering additives and should lead to improved safety levels. PMID:16730742

  19. 21 CFR 355.70 - Testing procedures for fluoride dentifrice drug products.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 5 2010-04-01 2010-04-01 false Testing procedures for fluoride dentifrice drug... SERVICES (CONTINUED) DRUGS FOR HUMAN USE ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures § 355.70 Testing procedures for fluoride dentifrice drug products. (a) A fluoride dentifrice...

  20. 21 CFR 355.70 - Testing procedures for fluoride dentifrice drug products.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 5 2013-04-01 2013-04-01 false Testing procedures for fluoride dentifrice drug... SERVICES (CONTINUED) DRUGS FOR HUMAN USE ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures § 355.70 Testing procedures for fluoride dentifrice drug products. (a) A fluoride dentifrice...

  1. 21 CFR 355.70 - Testing procedures for fluoride dentifrice drug products.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 5 2012-04-01 2012-04-01 false Testing procedures for fluoride dentifrice drug... SERVICES (CONTINUED) DRUGS FOR HUMAN USE ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures § 355.70 Testing procedures for fluoride dentifrice drug products. (a) A fluoride dentifrice...

  2. 21 CFR 355.70 - Testing procedures for fluoride dentifrice drug products.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 5 2011-04-01 2011-04-01 false Testing procedures for fluoride dentifrice drug... SERVICES (CONTINUED) DRUGS FOR HUMAN USE ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures § 355.70 Testing procedures for fluoride dentifrice drug products. (a) A fluoride dentifrice...

  3. 21 CFR 355.70 - Testing procedures for fluoride dentifrice drug products.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 5 2014-04-01 2014-04-01 false Testing procedures for fluoride dentifrice drug... SERVICES (CONTINUED) DRUGS FOR HUMAN USE ANTICARIES DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE Testing Procedures § 355.70 Testing procedures for fluoride dentifrice drug products. (a) A fluoride dentifrice...

  4. Laboratory testing of clinically approved drugs against Balamuthia mandrillaris.

    PubMed

    Kalsoom, Huma; Baig, Abdul Mannan; Khan, Naveed Ahmed; Siddiqui, Ruqaiyyah

    2014-09-01

    Balamuthia mandrillaris is a free-living protist pathogen that can cause life-threatening granulomatous amoebic encephalitis. Given the lack of effective available drugs against B. mandrillaris encephalitis with a mortality rate of more than 90%, here we screened drugs, targeting vital cellular receptors and biochemical pathways, that are already in approved clinical use for their potential clinical usefulness. Amoebicidal assays were performed by incubating B. mandrillaris with drugs (3 × 10(5) cells/0.5 mL/well) in phosphate buffered saline for 24 h and viability was determined using Trypan blue exclusion staining. For controls, amoebae were incubated with the solvent alone. To determine whether effects are reversible, B. mandrillaris were pre-exposed to drugs for 24 h, washed twice, and incubated with human brain microvascular endothelial cells, which constitute the blood-brain barrier as food source, for up to 48 h. Of the ten drugs tested, amlodipine, apomorphine, demethoxycurcumin, haloperidol, loperamide, prochlorperazine, procyclidine, and resveratrol showed potent amoebicidal effects, while amiodarone and digoxin exhibited minimal effectiveness. When pre-treated with these drugs, no viable trophozoites re-emerged, suggesting that drugs destroyed parasite irreversibly. Based on the in vitro assay, amlodipine, apomorphine, demethoxycurcumin, haloperidol, loperamide, prochlorperazine, procyclidine, and resveratrol are potential antimicrobials for further testing against B. mandrillaris encephalitis. These findings may provide novel strategies for therapy but further research is needed to determine clinical usefulness of aforementioned drugs against granulomatous amoebic encephalitis caused by B. mandrillaris, and other free-living amoebae, such as Acanthamoeba spp., and Naegleria fowleri. PMID:24875138

  5. 75 FR 59105 - Procedures for Transportation Workplace Drug and Alcohol Testing Programs: Federal Drug Testing...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2010-09-27

    ... Federal CCF.'' [74 FR 59196] Because many of the commenters were transportation industry employers, C/TPAs... in order for collectors, laboratories, and Medical Review Officers to know how to use the new form...'' after ``Marijuana Metabolite'' and ``BZE'' after ``Cocaine Metabolite'' to specify the drug analytes;...

  6. In Vitro Drug Sensitivity Tests to Predict Molecular Target Drug Responses in Surgically Resected Lung Cancer

    PubMed Central

    Miyazaki, Ryohei; Anayama, Takashi; Hirohashi, Kentaro; Okada, Hironobu; Kume, Motohiko; Orihashi, Kazumasa

    2016-01-01

    Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and anaplastic lymphoma kinase (ALK) inhibitors have dramatically changed the strategy of medical treatment of lung cancer. Patients should be screened for the presence of the EGFR mutation or echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene prior to chemotherapy to predict their clinical response. The succinate dehydrogenase inhibition (SDI) test and collagen gel droplet embedded culture drug sensitivity test (CD-DST) are established in vitro drug sensitivity tests, which may predict the sensitivity of patients to cytotoxic anticancer drugs. We applied in vitro drug sensitivity tests for cyclopedic prediction of clinical responses to different molecular targeting drugs. Methods The growth inhibitory effects of erlotinib and crizotinib were confirmed for lung cancer cell lines using SDI and CD-DST. The sensitivity of 35 cases of surgically resected lung cancer to erlotinib was examined using SDI or CD-DST, and compared with EGFR mutation status. Results HCC827 (Exon19: E746-A750 del) and H3122 (EML4-ALK) cells were inhibited by lower concentrations of erlotinib and crizotinib, respectively than A549, H460, and H1975 (L858R+T790M) cells were. The viability of the surgically resected lung cancer was 60.0 ± 9.8 and 86.8 ± 13.9% in EGFR-mutants vs. wild types in the SDI (p = 0.0003). The cell viability was 33.5 ± 21.2 and 79.0 ± 18.6% in EGFR mutants vs. wild-type cases (p = 0.026) in CD-DST. Conclusions In vitro drug sensitivity evaluated by either SDI or CD-DST correlated with EGFR gene status. Therefore, SDI and CD-DST may be useful predictors of potential clinical responses to the molecular anticancer drugs, cyclopedically. PMID:27070423

  7. Rapid and semi-quantitative presumptive tests for opiate drugs.

    PubMed

    Choodum, Aree; Daeid, Niamh Nic

    2011-10-30

    Digital image analysis was applied to the products of simple colour presumptive tests for opiates. Adobe Photoshop software was used for colour analysis to obtain analytical data in the form of a Red Green Blue (RGB) value. Calibration curves were developed for morphine, codeine, and diamorphine hydrochloride and the developed tests successfully applied to seized heroin samples to demonstrate the application of the technique in a forensic case context. Good agreement with gas chromatographic quantification results was obtained for the illicit samples analysed and a wide linear range and low detection limit for all drugs under test facilitated the application to illicit samples. The results show great potential for use as a semi-quantitative field test for illicit drug compounds. PMID:22063543

  8. 10 CFR 26.405 - Drug and alcohol testing.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... standards contained in 29 CFR 1904.7, and subsequent amendments thereto, and results in death, days away from work, restricted work, transfer to another job, medical treatment beyond first aid, loss of... CFR Part 40 and subsequent amendments thereto. (f) Testing of urine specimens for drugs and...

  9. 77 FR 39194 - Combined Drug and Alcohol Testing Programs

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-07-02

    ..., 2000 (65 FR 19477-19478), as well as at http://DocketsInfo.dot.gov . Docket: Background documents or... Standards rule (72 FR 6884, February 13, 2007) established a separate subpart in part 91 to govern..., the FAA published a final rule titled ``Drug and Alcohol Testing Program'' (74 FR 22653) that...

  10. NCAA Drug-Testing Program 2010-11

    ERIC Educational Resources Information Center

    National Collegiate Athletic Association (NJ1), 2010

    2010-01-01

    The National Collegiate Athletic Association (NCAA) Drug-Testing Program was created to protect the health and safety of student-athletes and to ensure that no one participant might have an artificially induced advantage or be pressured to use chemical substances. This publication describes this program in the following chapters: (1) NCAA…

  11. 14 CFR 120.117 - Implementing a drug testing program.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... Maintenance Inspector that you will comply with this part and 49 CFR part 40. (3) You are required to obtain... statement indicating that: your company will comply with this part and 49 CFR part 40; and, if you are a... 14 Aeronautics and Space 3 2012-01-01 2012-01-01 false Implementing a drug testing program....

  12. 14 CFR 120.117 - Implementing a drug testing program.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... Maintenance Inspector that you will comply with this part and 49 CFR part 40. (3) You are required to obtain... statement indicating that: your company will comply with this part and 49 CFR part 40; and, if you are a... 14 Aeronautics and Space 3 2011-01-01 2011-01-01 false Implementing a drug testing program....

  13. 14 CFR 120.117 - Implementing a drug testing program.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... Maintenance Inspector that you will comply with this part and 49 CFR part 40. (3) You are required to obtain... statement indicating that: your company will comply with this part and 49 CFR part 40; and, if you are a... 14 Aeronautics and Space 3 2013-01-01 2013-01-01 false Implementing a drug testing program....

  14. NCAA[R] Drug-Testing Program, 1999-2000.

    ERIC Educational Resources Information Center

    Halpin, Ty, Ed.

    The drug testing program supports NCAA's goal to protect the health and safety of student-athletes competing for their institutions, while reaffirming the organization's commitment to fair and equitable competition. Proposal Nos. 30 and 52-54 provide a program for the NCAA's members to ensure that no one athlete has a chemically-induced advantage…

  15. Workplace drug testing in Italy: findings about second-stage testing.

    PubMed

    Vignali, Claudia; Stramesi, Cristiana; Morini, Luca; San Bartolomeo, Paolo; Groppi, Angelo

    2015-03-01

    Workplace Drug Testing (WDT) in Italy includes two levels of monitoring: a first stage concerning drug testing on urine samples and a second involving both urine and hair analysis. The second stage is performed only on workers who tested positive at the first level. We analyzed urine and hair specimens from 120 workers undergoing second-level testing between 2009 and 2012. Eighty percent of them had tested positive for cannabinoids during the first level analysis, and 15.8% for cocaine. Both urine and hair samples were analyzed in order to find the following drugs of abuse: amphetamines, buprenorphine, cannabinoids, cocaine, ecstasy, methadone, and opiates. Urine analyses were performed by immunological screening (EMIT); urine confirmatory tests and hair analyses were performed by gas chromatography-mass spectrometry (GC-MS). As regards second-stage testing on urine samples, 71.2% of workers were always negative, whereas 23.9% tested positive at least once for cannabinoids and 2.5% for cocaine. Hair analyses produced surprising results: 61.9% of hair samples tested negative, only 6.2% tested positive for cannabinoids, whereas 28.8% tested positive for cocaine. These findings confirm that second-level surveillance of WDT, which includes hair analysis, is very effective because it highlights drug intake - sometimes heavy - that cannot be revealed only through urine analyses. The employees for whom drug addiction is proved can begin rehabilitation, while keeping their job. Eventually, our results confirmed the widespread and undeclared use of cocaine in Italy. PMID:24652693

  16. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia.

    PubMed

    Matsuno, Osamu; Okubo, Toshiyuki; Hiroshige, Shigeo; Takenaka, Rhyuichi; Ono, Emiko; Ueno, Takuya; Nureki, Shinichi; Ando, Masaru; Miyazaki, Eishi; Kumamoto, Toshihide

    2007-05-01

    Diagnosis of drug-induced pneumonia, which represents pulmonary toxicity caused by certain drugs, is difficult, as a large number of different drugs can elicit various immune-mediated diseases with distinct pathomechanisms. The drug-induced lymphocyte stimulation test (DLST) is widely used for diagnosing drug-induced pneumonia in Japan. Recent reports, however, indicate that DLST is not reliable for diagnosis of drug-induced pneumonia. To diagnose drug-induced pneumonia, a provocation test with the suspected drug is the most reliable method of assessing the relationship between the drug and pneumonia. We examined the correlation between the DLST and the provocation test in 6 cases of suspected drug-induced pneumonia. DLST was performed in all of the patients. The causes of pneumonia in all patients were confirmed by a provocation test. The DLST was positive in 3 of 6 cases of suspected drug-induced pneumonia, but the suspected drugs were ruled out by the provocation test. If we had relied solely on the DLST, these 3 cases would have been labeled as false allergy. The results of the DLST did not coincide with the results of the provocation test in any of the cases. Our results suggest that the DLST is not useful for the diagnosis of drug-induced pneumonia. Following provocation with the causative drug, reappearance of pulmonary infiltration was not observed in any of the cases. These findings indicate that a carefully performed provocation test is the safe and most reliable method. PMID:17464103

  17. Comparison of Urine and Oral Fluid for Workplace Drug Testing

    PubMed Central

    Casolin, Armand

    2016-01-01

    Aims To determine the relative detection rates of urine versus oral fluid testing in a safety sensitive industry and the correlation with diagnosed substance use disorders and possible impairment at work. Methods The trial involved 1,500 paired urine and oral fluid tests performed in accordance with Australian Standard/New Zealand Standard (AS/NZS) 4308:2008 and AS 4760:2006. Workers who returned a positive test were screened for substance use disorders, as defined by DSM-5, and for possible impairment at work following that particular episode of substance use. Results Substances were detected in 3.7% (n = 56) of urine samples and 0.5% (n = 8) of oral fluid samples (p < 0.0001). One worker (0.07%) had a substance detected on oral fluid alone versus 49 workers (3.3%) who had substances detected on urine alone. Twelve workers returned a positive result, defined as being consistent with the use of an illicit drug or a controlled substance without a clinical indication and prescription. Nine workers tested positive on urine alone, one on oral fluid alone and two on both (p = 0.0114). Of note, 6/11 workers who tested positive on urine had possible impairment at work and 2/11 had a substance use disorder versus 2/3 and 0/3, respectively, who tested positive on oral fluid. Conclusions Urine drug testing performed in accordance with AS/NZS 4308:2008 is more likely to detect overall substance use and illicit drug use than oral fluid testing conducted in accordance with AS 4760:2006. Urine testing performed in accordance with AS/NZS 4308:2008 may also be more likely to detect workers with possible impairment at work and substance use disorders than oral fluid testing performed in accordance with AS 4760:2006. PMID:27344042

  18. 49 CFR 40.205 - How are drug test problems corrected?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 1 2010-10-01 2010-10-01 false How are drug test problems corrected? 40.205... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Problems in Drug Tests § 40.205 How are drug test problems...), you must try to correct the problem promptly, if doing so is practicable. You may conduct...

  19. 49 CFR 40.205 - How are drug test problems corrected?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 1 2011-10-01 2011-10-01 false How are drug test problems corrected? 40.205... WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Problems in Drug Tests § 40.205 How are drug test problems...), you must try to correct the problem promptly, if doing so is practicable. You may conduct...

  20. 14 CFR 120.123 - Drug testing outside the territory of the United States.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 14 Aeronautics and Space 3 2014-01-01 2014-01-01 false Drug testing outside the territory of the United States. 120.123 Section 120.123 Aeronautics and Space FEDERAL AVIATION ADMINISTRATION, DEPARTMENT... OPERATIONS DRUG AND ALCOHOL TESTING PROGRAM Drug Testing Program Requirements § 120.123 Drug testing...

  1. 14 CFR 120.123 - Drug testing outside the territory of the United States.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 14 Aeronautics and Space 3 2013-01-01 2013-01-01 false Drug testing outside the territory of the United States. 120.123 Section 120.123 Aeronautics and Space FEDERAL AVIATION ADMINISTRATION, DEPARTMENT... OPERATIONS DRUG AND ALCOHOL TESTING PROGRAM Drug Testing Program Requirements § 120.123 Drug testing...

  2. Drug Testing in Children with Excessive Daytime Sleepiness During Multiple Sleep Latency Testing

    PubMed Central

    Katz, Eliot S.; Maski, Kiran; Jenkins, Amanda J.

    2014-01-01

    Study Objective: To determine the incidence of positive drug screens in children undergoing a multiple sleep latency test (MSLT) for evaluation of excessive daytime sleepiness (EDS). Methods: A retrospective analysis was performed in children evaluated at the Boston Children's Hospital Sleep Center between 1998 and 2013 who underwent MSLT for EDS with a concurrent urine and/or serum drug screen. Results: A total of 210 MSLTs were accompanied by drug testing. Children were 12.7 ± 3.7 years old (mean ± SD), 43% were female, and 24% had narcolepsy. Positive tests were obtained in 32% for caffeine, 5% for prescription medications, and 4% for over-the-counter drugs. No drugs of abuse were identified. Children testing positive for caffeine were older (13.8 ± 3.5 vs. 12.4 ± 3.7) and more likely female (59% vs. 36%), but did not differ in MSLT or overnight polysomnographic parameters compared to children without caffeine detected. Overall, only 14% had specific documentation regarding caffeine intake, though 90% were referred from a sleep clinic. Of the children testing positive for caffeine, 5% acknowledged use, 3% denied use, and 92% did not have a documented caffeine intake history during their sleep clinic visit. Conclusions: Routine drug testing for drugs of abuse during an MSLT for EDS yielded no positive results over a 15-year period, indicating that this routine practice is unnecessary in our pediatric population without specific concerns. However, objective evidence for caffeine exposure was found in 32% of tested children undergoing an MSLT. Sleep physicians rarely documented the caffeine intake history during clinic visits for EDS. Citation: Katz ES, Maski K, Jenkins AJ. Drug testing in children with excessive daytime sleepiness during multiple sleep latency testing. J Clin Sleep Med 2014;10(8):897-901. PMID:25126037

  3. 10 CFR 707.7 - Random drug testing requirements and identification of testing designated positions.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... (HRP), codified at 10 CFR part 712. HRP employees will be subject to the drug testing standards of this... Facility (FFTF); High Flux Beam Reactor (HFBR); High Flux Isotope Reactor (HFIR); K Production Reactor...

  4. 10 CFR 707.7 - Random drug testing requirements and identification of testing designated positions.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... (HRP), codified at 10 CFR part 712. HRP employees will be subject to the drug testing standards of this... Facility (FFTF); High Flux Beam Reactor (HFBR); High Flux Isotope Reactor (HFIR); K Production Reactor...

  5. 10 CFR 707.7 - Random drug testing requirements and identification of testing designated positions.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... (HRP), codified at 10 CFR part 712. HRP employees will be subject to the drug testing standards of this... Facility (FFTF); High Flux Beam Reactor (HFBR); High Flux Isotope Reactor (HFIR); K Production Reactor...

  6. 10 CFR 707.7 - Random drug testing requirements and identification of testing designated positions.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... (HRP), codified at 10 CFR part 712. HRP employees will be subject to the drug testing standards of this... Facility (FFTF); High Flux Beam Reactor (HFBR); High Flux Isotope Reactor (HFIR); K Production Reactor...

  7. 10 CFR 707.7 - Random drug testing requirements and identification of testing designated positions.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... (HRP), codified at 10 CFR part 712. HRP employees will be subject to the drug testing standards of this... Facility (FFTF); High Flux Beam Reactor (HFBR); High Flux Isotope Reactor (HFIR); K Production Reactor...

  8. HIV Rapid Testing in Drug Treatment: Comparison Across Treatment Modalities

    PubMed Central

    Schwartz, Robert P.; Stitzer, Maxine L.; Feaster, Daniel J.; Korthuis, P. Todd; Alvanzo, Anika A. H.; Winhusen, T. M.; Donnard, Lillian; Snead, Ned; Metsch, L. R.

    2012-01-01

    Despite high rates of risky behavior among patients, many drug abuse treatment programs do not provide on-site HIV testing. This secondary analysis examined differences in outcome by program modality from a multi-site trial in which 1,281 HIV-negative patients in 3 methadone programs, 7 non-methadone outpatient programs, and 3 residential programs were randomly assigned to: (1) off-site referral for HIV risk reduction counseling and testing; or on-site rapid testing (2) with or (3) without risk reduction counseling. The parent study using generalized estimating equations with site as a cluster variable found significantly higher rates of HIV testing and feedback of results by 1 month post-enrollment for the combined on-site conditions compared to the offsite condition (RR=4.52, 97.5% CI (3.57, 5.72). Utilizing the same statistical approach, we found neither significant treatment modality nor significant treatment modality by testing condition interaction effects either for receipt of HIV test results at 1 month or for sexual or drug use HIV-risk behaviors at 6-month follow-up. On-site HIV testing is effective across treatment modalities for achieving high rates of testing and results feedback. All programs should be encouraged to adopt or expand this service. PMID:23021496

  9. Equipment for drug release testing of medicated chewing gums.

    PubMed

    Kvist, L C; Andersson, S B; Berglund, J; Wennergren, B; Fors, S M

    2000-04-01

    An apparatus was specially designed and constructed for release testing of medicated chewing gums. The adjustable instrumental settings such as temperature, chewing frequency, chewing time, volume of test medium, distance between the jaws and twisting angle increased the versatility of the apparatus. Selection of the test medium was also an important parameter. Each sample was kneaded mechanically in separate test chambers and the drug release was followed by sampling and HPLC analysis. Different gum formulations were tested and the obtained results demonstrated satisfactory release curves for a variety of formulations and active ingredients. The tested gum formulations comprised nicotine, meclizine, dimenhydrinate and xylitol. The apparatus proved to be suitable in product control of commercial batches but also a useful tool in the research and development of medicated gum formulations. PMID:10766358

  10. Simple Model for Testing Drugs against Nonreplicating Mycobacterium tuberculosis▿ †

    PubMed Central

    Sala, Claudia; Dhar, Neeraj; Hartkoorn, Ruben C.; Zhang, Ming; Ha, Young Hwan; Schneider, Patricia; Cole, Stewart T.

    2010-01-01

    Nonreplicating or dormant cells of Mycobacterium tuberculosis constitute a challenge to tuberculosis (TB) therapy because of their tolerance or phenotypic resistance to most drugs. Here, we propose a simple model for testing drugs against nongrowing cells that exploits the 18b strain of M. tuberculosis, a streptomycin (STR)-dependent mutant. Optimal conditions were established that allowed 18b cells to replicate in the presence of STR and to survive, but not multiply, following withdrawal of STR. In the presence of the antibiotic, M. tuberculosis 18b was susceptible to the currently approved TB drugs, isoniazid (INH) and rifampin (RIF), and to the experimental drugs TMC207, PA-824, meropenem (MER), benzothiazinone (BTZ), and moxifloxacin (MOXI). After STR depletion, the strain displayed greatly reduced susceptibility to the cell wall inhibitors INH and BTZ but showed increased susceptibility to RIF and PA-824, while MOXI and MER appeared equipotent under both conditions. The same potency ranking was found against nonreplicating M. tuberculosis 18b after in vivo treatment of chronically infected mice with five of these drugs. Despite the growth arrest, strain 18b retains significant metabolic activity in vitro, remaining positive in the resazurin reduction assay. Upon adaption to a 96-well format, this assay was shown to be suitable for high-throughput screening with strain 18b to find new inhibitors of dormant M. tuberculosis. PMID:20679505

  11. Rapid drug susceptibility test of mycobacterium tuberculosis by bioluminescence sensor

    NASA Astrophysics Data System (ADS)

    Lu, Bin; Xu, Shunqing; Chen, Zifei; Zhou, Yikai

    2001-09-01

    With the persisting increase of drug-resistant stains of M. Tuberculosis around the world, rapid and sensitive detection of antibiotic of M. Tuberculosis is becoming more and more important. In the present study, drug susceptibility of M. tuberculosis were detected by recombination mycobacteriophage combined with bioluminescence sensor. It is based on the use of recombination mycobacteriophage which can express firefly luciferase when it infects viable mycobacteria, and can effectively produce quantifiable photon. Meanwhile, in mycobacterium cells treated with active antibiotic, no light is observed. The emitted light is recorded by a bioluminscence sensor, so the result of drug-resistant test can be determined by the naked eye. 159 stains of M. tuberculosis were applied to this test on their resistant to rifampin, streptomycin and isoniazid. It is found that the agreement of this assay with Liewenstein- Jensen slat is: rifampin 95.60 percent, isoniazid 91.82 percent, streptomycin 88.68 percent, which showed that it is a fast and practical method to scene and detect drug resistant of mycobacterium stains.

  12. Breath tests to phenotype drug disposition in oncology.

    PubMed

    Opdam, Frans L; Modak, Anil S; Gelderblom, Hans; Guchelaar, Henk-Jan

    2013-11-01

    Breath tests (BTs) have been investigated as diagnostic tools to phenotype drug disposition in cancer patients in the pursuit to individualize drug treatment. The choice of the right phenotype probe is crucial and depends on the metabolic pathway of the anticancer agent of interest. BTs using orally or intravenously administered selective non-radioactive (13)C-labeled probes to non-invasively evaluate dihydropyrimidine dehydrogenase, cytochrome P450 (CYP) 3A4, and CYP2D6 enzyme activity have been published. Clinically, a (13)C-dextromethorphan BT to predict endoxifen levels in breast cancer patients and a (13)C-uracil BT to predict fluoropyrimidine toxicity in colorectal cancer patients are most promising. However, the clinical benefit and cost effectiveness of these phenotype BTs need to be determined in order to make the transition from an experimental setting to clinical practice as companion diagnostic tests. PMID:23868281

  13. Olodaterol and vilanterol detection in sport drug testing.

    PubMed

    Chundela, Zdenek; Große, Joachim

    2015-01-01

    The possibility of the detection of olodaterol and vilanterol, two novel β2 -agonists, in human urine for the purpose of sport drug testing was investigated. Compounds of interest were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) employing methods commonly used in the World Anti-Doping Agency (WADA) accredited laboratories. For both substances, the respective parent compound was found to be a suitable target analyte for monitoring therapeutic dose administration. PMID:26593301

  14. Template synthesized chitosan nano test tubes for drug delivery applications

    NASA Astrophysics Data System (ADS)

    Perry, Jillian L. Moulton

    There is tremendous current interest in developing nanoscale drug delivery vehicles. Though intensive efforts have focused on developing spherical drug delivery vehicles, cylindrically shaped vehicles such as nanotubes offer many advantages. Typically, nanotubes can carry a larger inner payload than nanoparticles of the same diameter. Also, we can prepare nanotubes in templates whose geometries can be controlled, in turn allowing precise control over the length and diameter of the tubes. In addition, template synthesized nanotubes can be differentially functionalized on the inner and outer surfaces. Furthermore, templates that are closed on one end can be used to fabricate nano test tubes (closed on one end). The geometry of these nano test tubes allows them to be easily filled with a payload, the open end sealed with a nanoparticle to protect the payload from leaking out, and then the exterior of the tube can be functionalized with a targeting moiety. In an effort to develop such a system, we explored the fabrication of chitosan nano test tubes. Defect-free, chitosan nano test tubes of uniform size were synthesized within the pores of a nanoporous alumina template membrane. While the nano test tubes remained within the template membrane, their inner cavities were filled with a model payload. The payload was then trapped inside the nano test tubes by sealing the open ends of the tubes with latex nanoparticle caps. For proof-of-principle studies, imine linkages were used to attach the caps to the nano test tubes. To create a self-disassembling system, disulfide chemistry was used to covalently cap the nano test tubes. Once removed from the template, the exterior of the nano test tubes were modified with a targeting moiety, allowing them to be targeted to pathological sites. We have also shown that the chitosan nano test tubes are biodegradable by two systems: enzymatic cleavage by lysozymes and disulfide cleavage of the crosslinker by reducing environments

  15. Segmental hair testing to disclose chronic exposure to psychoactive drugs.

    PubMed

    Marchei, Emilia; Palmi, Ilaria; Pichini, Simona; Pacifici, Roberta; Anton Airaldi, Ileana-Rita; Costa Orvay, Juan Antonio; García Serra, Joan; Bonet Serra, Bartolomé; García-Algar, Óscar

    2016-01-01

    This study presents the case of a 4-year-old healthy child admitted to the paediatric ward for suspected accidental intoxication due to ingestion of narcoleptic drugs (methylphenidate, sertraline and quetiapine), taken on a regular basis by his 8-year-old brother affected by Asperger syndrome.Intoxication can be objectively assessed by measurements of drugs and metabolites in biological matrices with short-term (blood and urine) or long-term (hair) detection windows. At the hospital, the child's blood and urine were analysed by immunoassay (confirmed by liquid chromatography-mass spectrometry), and sertraline and quetiapine and their metabolites were identified. The suspicion that the mother administered drugs chronically prompted the analysis of six, consecutive 2-cm segments of the child's hair, using ultra-high performance liquid chromatography-tandem mass spectrometry, thereby accounting for ingestion over the previous 12 months. Quetiapine was found in the first four segments with a mean concentration of 1.00 ng/mg ± 0.94 ng/mg hair while sertraline and its metabolite, desmethyl-sertraline, were found in all segments with a mean concentration of 2.65 ± 0.94 ng/mg and 1.50 ± 0.94 ng/mg hair, respectively. Hair analyses were negative for methylphenidate and its metabolite (ritalinic acid). Biological matrices testing for psychoactive drugs disclosed both acute and chronic intoxication with quetiapine and sertraline administered by the mother. PMID:27399225

  16. 10 CFR 26.65 - Pre-access drug and alcohol testing.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 1 2010-01-01 2010-01-01 false Pre-access drug and alcohol testing. 26.65 Section 26.65... § 26.65 Pre-access drug and alcohol testing. (a) Purpose. This section contains pre-access testing... days. If an individual has negative results from drug and alcohol tests that were conducted under...

  17. Differentiation between drug use and environmental contamination when testing for drugs in hair.

    PubMed

    Tsanaclis, Lolita; Wicks, John F C

    2008-03-21

    The differentiation between systemic exposure and external contamination for certain drug groups has been frequently referred to as one of the limitations of in drug testing in hair. When hair samples are used, three steps are usually employed in order to minimise the possibility of external contamination causing a misinterpretation. The first consists of decontaminating hair samples by washing the hair before analysis, the second is the detection of the relevant metabolites in the hair samples and the third is the use of cut-off levels. Difficulty in the interpretation arises when metabolites are not detected either due to external contamination of the hair or low doses of the drugs used. A wash protocol needs to be practical and ideally remove any drug deposited on the external portion of the hair. We propose an additional step that helps considerably in the interpretation of the results with the aim to establish a consensus: the analysis of the wash residue (W) and its comparison with the levels detected in hair (H). The wash residue is the remainder of a quick wash with methanol which is dried and reconstituted in buffer before analysis. The detection of small quantities of analytes that are not susceptible to external contamination in the wash residue, such as metabolites or drugs such as dihydrocodeine, indicates that the washing procedure is in fact able to remove drugs from the hair shaft. Where the W/H ratio is less then 0.1 or null, it would tend to indicate drug use as opposed to environmental contamination. Where the W/H ratio is above 0.1 but less than 0.5, it is likely to indicate possible use possibly combined with a level of external contamination. A W/H ratio greater than 0.5 is likely to indicate that the source of most of the drug in the wash residue is from external contamination. In this last case, the source of levels detected in the hair is questionable, as it is not possible to be absolutely sure that all external contamination was removed

  18. 78 FR 39190 - Revisions to Fitness for Duty Programs' Drug Testing Requirements

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-07-01

    ... REGULATORY COMMISSION 10 CFR Part 26 RIN 3150-AI67 Revisions to Fitness for Duty Programs' Drug Testing... effort to amend its regulations regarding drug testing requirements in NRC licensees' fitness for...

  19. Pumpless microfluidic platform for drug testing on human skin equivalents.

    PubMed

    Abaci, Hasan Erbil; Gledhill, Karl; Guo, Zongyou; Christiano, Angela M; Shuler, Michael L

    2015-02-01

    Advances in bio-mimetic in vitro human skin models increase the efficiency of drug screening studies. In this study, we designed and developed a microfluidic platform that allows for long-term maintenance of full thickness human skin equivalents (HSE) which are comprised of both the epidermal and dermal compartments. The design is based on the physiologically relevant blood residence times in human skin tissue and allows for the establishment of an air-epidermal interface which is crucial for maturation and terminal differentiation of HSEs. The small scale of the design reduces the amount of culture medium and the number of cells required by 36 fold compared to conventional transwell cultures. Our HSE-on-a-chip platform has the capability to recirculate the medium at desired flow rates without the need for pump or external tube connections. We demonstrate that the platform can be used to maintain HSEs for three weeks with proliferating keratinocytes similar to conventional HSE cultures. Immunohistochemistry analyses show that the differentiation and localization of keratinocytes was successfully achieved, establishing all sub-layers of the epidermis after one week. Basal keratinocytes located at the epidermal-dermal interface remain in a proliferative state for three weeks. We use a transdermal transport model to show that the skin barrier function is maintained for three weeks. We also validate the capability of the HSE-on-a-chip platform to be used for drug testing purposes by examining the toxic effects of doxorubucin on skin cells and structure. Overall, the HSE-on-a-chip is a user-friendly and cost-effective in vitro platform for drug testing of candidate molecules for skin disorders. PMID:25490891

  20. 75 FR 79308 - Alcohol and Drug Testing: Determination of Minimum Random Testing Rates for 2011

    Federal Register 2010, 2011, 2012, 2013, 2014

    2010-12-20

    .... SUMMARY: Using data from Management Information System annual reports, FRA has determined that the 2009... taken from FRA's Management Information System. Based on this data, the Administrator publishes a... Drug and Alcohol Testing Rates In a final rule published on December 2, 1994 (59 FR 62218),...

  1. 75 FR 1547 - Alcohol and Drug Testing: Determination of Minimum Random Testing Rates for 2010

    Federal Register 2010, 2011, 2012, 2013, 2014

    2010-01-12

    ... Transportation (DOT). ACTION: Notice of Determination. SUMMARY: Using data from Management Information System... alcohol program data taken from FRA's Management Information System. Based on this data, the Administrator..., 1994 (59 FR 62218), FRA announced that it will set future minimum random drug and alcohol testing...

  2. 49 CFR 40.87 - What are the cutoff concentrations for drug tests?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 1 2011-10-01 2011-10-01 false What are the cutoff concentrations for drug tests... concentrations for drug tests? (a) As a laboratory, you must use the cutoff concentrations displayed in the following table for initial and confirmatory drug tests. All cutoff concentrations are expressed...

  3. 49 CFR 40.87 - What are the cutoff concentrations for drug tests?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 1 2010-10-01 2010-10-01 false What are the cutoff concentrations for drug tests... concentrations for drug tests? (a) As a laboratory, you must use the cutoff concentrations displayed in the following table for initial and confirmatory drug tests. All cutoff concentrations are expressed...

  4. 49 CFR 40.199 - What problems always cause a drug test to be cancelled?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 1 2010-10-01 2010-10-01 false What problems always cause a drug test to be cancelled? 40.199 Section 40.199 Transportation Office of the Secretary of Transportation PROCEDURES FOR TRANSPORTATION WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Problems in Drug Tests § 40.199 What problems...

  5. 49 CFR 40.207 - What is the effect of a cancelled drug test?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 1 2011-10-01 2011-10-01 false What is the effect of a cancelled drug test? 40.207 Section 40.207 Transportation Office of the Secretary of Transportation PROCEDURES FOR TRANSPORTATION WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Problems in Drug Tests § 40.207 What is the effect...

  6. Drug Testing Guidelines and Practices for Juvenile Probation and Parole Agencies.

    ERIC Educational Resources Information Center

    American Probation and Parole Association, Lexington, KY.

    This document, intended as a resource manual, provides guidelines on drug testing. These topics are covered: (1) National Institute on Drug Abuse guidelines applicability; (2) introduction to legal issues, drug testing in juvenile probation and parole, and juvenile law; (3) mission of a juvenile parole agency; (4) purpose of testing; (5) drug…

  7. 49 CFR 40.207 - What is the effect of a cancelled drug test?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 1 2010-10-01 2010-10-01 false What is the effect of a cancelled drug test? 40.207 Section 40.207 Transportation Office of the Secretary of Transportation PROCEDURES FOR TRANSPORTATION WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Problems in Drug Tests § 40.207 What is the effect...

  8. 49 CFR 199.119 - Reporting of anti-drug testing results.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... 49 Transportation 3 2013-10-01 2013-10-01 false Reporting of anti-drug testing results. 199.119 Section 199.119 Transportation Other Regulations Relating to Transportation (Continued) PIPELINE AND HAZARDOUS MATERIALS SAFETY ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL TESTING Drug Testing §...

  9. An Alternative to the Physiological Psychology Laboratory: Identification of an Unknown Drug Through Behavioral Testing.

    ERIC Educational Resources Information Center

    Schumacher, Susan J.

    1982-01-01

    A laboratory project introduced physiological psychology students to research by requiring them to identify an unknown drug given to laboratory animals. Students read material about drugs and animal drug studies, designed behavioral tests, constructed the testing apparatus, conducted the tests, and wrote progress reports. (SR)

  10. Results of the Queensland 2007-2012 roadside drug testing program: The prevalence of three illicit drugs.

    PubMed

    Davey, Jeremy; Armstrong, Kerry; Martin, Peter

    2014-04-01

    The purpose of this investigation is to present an overview of roadside drug driving enforcement and detections in Queensland, Australia since the introduction of oral fluid screening. Drug driving is a problematic issue for road safety and investigations of the prevalence and impact of drug driving suggest that, in particular, the use of illicit drugs may increase a driver's involvement in a road crash when compared to a driver who is drug free. In response to the potential increased crash involvement of drug impaired drivers, Australian police agencies have adopted the use of oral fluid analysis to detect the presence of illicit drugs in drivers. This paper describes the results of roadside drug testing for over 80,000 drivers in Queensland, Australia, from December 2007 to June 2012. It provides unique data on the prevalence of methamphetamine, cannabis and ecstasy in the screened population for the period. When prevalence rates are examined over time, drug driving detection rates have almost doubled from around 2.0% at the introduction of roadside testing operations to just under 4.0% in the latter years. The most common drug type detected was methamphetamine (40.8%) followed by cannabis (29.8%) and methamphetamine/cannabis combination (22.5%). By comparison, the rate of ecstasy detection was very low (1.7%). The data revealed a number of regional, age and gender patterns and variations of drug driving across the state. Younger drivers were more likely to test positive for cannabis whilst older drivers were more likely to test positive for methamphetamine. The overall characteristics of drivers who tested positive to the presence of at least one of the target illicit drugs are they are likely to be male, aged 30-39 years, be driving a car on Friday, Saturday or Sunday between 6:00 pm and 6:00 am and to test positive for methamphetamine. PMID:24389088

  11. Fatal Crashes from Drivers Testing Positive for Drugs in the U.S., 1993–2010

    PubMed Central

    Stimpson, Jim P.; Pagán, José A.

    2014-01-01

    Objective Illegal drug use is a persistent problem, prescription drug abuse is on the rise, and there is clinical evidence that drug use reduces driving performance. This study describes trends in characteristics of drivers involved in fatal motor vehicle crashes who test positive for drugs. Methods We used the Fatality Analysis Reporting System—a census of motor vehicle crashes resulting in at least one fatality on U.S. public roads—to investigate suspected drug use for the period 1993–2010. Results Drugged drivers who were tested for drug use accounted for 11.4% of all drivers involved in fatal motor vehicle crashes in 2010. Drugged drivers are increasingly likely to be older drivers, and the percentage using multiple drugs increased from 32.6% in 1993 to 45.8% in 2010. About half (52.4%) of all drugged drivers used alcohol, but nearly three-quarters of drivers testing positive for cocaine also used alcohol. Prescription drugs accounted for the highest fraction of drugs used by drugged drivers in fatal crashes in 2010 (46.5%), with much of the increase in prevalence occurring since the mid-2000s. Conclusions The profile of a drugged driver has changed substantially over time. An increasing share of these drivers is now testing positive for prescription drugs, cannabis, and multiple drugs. These findings have implications for developing interventions to address the changing nature of drug use among drivers in the U.S. PMID:24982537

  12. Drug Testing. ERIC Digest Series Number EA35 (Revised).

    ERIC Educational Resources Information Center

    Klauke, Amy; Hadderman, Margaret

    Despite privacy concerns, school administrators are feeling pressure to adopt urgent measures to keep drugs and alcohol from further endangering our youth's well-being and undermining staff performance. This urgency is reinforced by a national anti-drug campaign and Congressional passage of the Drug-Free Workplace Act (1988) and the Drug-Free…

  13. 21 CFR 862.3645 - Neuroleptic drugs radioreceptor assay test system.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 8 2011-04-01 2011-04-01 false Neuroleptic drugs radioreceptor assay test system. 862.3645 Section 862.3645 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  14. 21 CFR 862.3645 - Neuroleptic drugs radioreceptor assay test system.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 8 2010-04-01 2010-04-01 false Neuroleptic drugs radioreceptor assay test system. 862.3645 Section 862.3645 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  15. 21 CFR 350.60 - Guidelines for effectiveness testing of antiperspirant drug products.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 5 2013-04-01 2013-04-01 false Guidelines for effectiveness testing of antiperspirant drug products. 350.60 Section 350.60 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF... because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food...

  16. 21 CFR 350.60 - Guidelines for effectiveness testing of antiperspirant drug products.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 5 2012-04-01 2012-04-01 false Guidelines for effectiveness testing of antiperspirant drug products. 350.60 Section 350.60 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF... because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food...

  17. 21 CFR 350.60 - Guidelines for effectiveness testing of antiperspirant drug products.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 5 2014-04-01 2014-04-01 false Guidelines for effectiveness testing of antiperspirant drug products. 350.60 Section 350.60 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF... because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food...

  18. 21 CFR 862.3645 - Neuroleptic drugs radioreceptor assay test system.

    Code of Federal Regulations, 2014 CFR

    2014-04-01

    ... 21 Food and Drugs 8 2014-04-01 2014-04-01 false Neuroleptic drugs radioreceptor assay test system. 862.3645 Section 862.3645 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  19. 21 CFR 862.3645 - Neuroleptic drugs radioreceptor assay test system.

    Code of Federal Regulations, 2012 CFR

    2012-04-01

    ... 21 Food and Drugs 8 2012-04-01 2012-04-01 false Neuroleptic drugs radioreceptor assay test system. 862.3645 Section 862.3645 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  20. 21 CFR 862.3645 - Neuroleptic drugs radioreceptor assay test system.

    Code of Federal Regulations, 2013 CFR

    2013-04-01

    ... 21 Food and Drugs 8 2013-04-01 2013-04-01 false Neuroleptic drugs radioreceptor assay test system. 862.3645 Section 862.3645 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF HEALTH AND HUMAN SERVICES (CONTINUED) MEDICAL DEVICES CLINICAL CHEMISTRY AND CLINICAL TOXICOLOGY DEVICES Clinical...

  1. 21 CFR 350.60 - Guidelines for effectiveness testing of antiperspirant drug products.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... 21 Food and Drugs 5 2011-04-01 2011-04-01 false Guidelines for effectiveness testing of antiperspirant drug products. 350.60 Section 350.60 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF... because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food...

  2. 21 CFR 350.60 - Guidelines for effectiveness testing of antiperspirant drug products.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... 21 Food and Drugs 5 2010-04-01 2010-04-01 false Guidelines for effectiveness testing of antiperspirant drug products. 350.60 Section 350.60 Food and Drugs FOOD AND DRUG ADMINISTRATION, DEPARTMENT OF... because of minor variations in formulation. To assure the effectiveness of an antiperspirant, the Food...

  3. Genetically Defined Strains in Drug Development and Toxicity Testing.

    PubMed

    Festing, Michael F W

    2016-01-01

    There is growing concern about the poor quality and lack of repeatability of many pre-clinical experiments involving laboratory animals. According to one estimate as much as $28 billion is wasted annually in the USA alone in such studies. A decade ago the FDA's "Critical path" white paper noted that "The traditional tools used to assess product safety-animal toxicology and outcomes from human studies-have changed little over many decades and have largely not benefited from recent gains in scientific knowledge. The inability to better assess and predict product safety leads to failures during clinical development and, occasionally, after marketing." Repeat-dose 28-days and 90-days toxicity tests in rodents have been widely used as part of a strategy to assess the safety of drugs and chemicals but their repeatability and power to detect adverse effects have not been formally evaluated.The guidelines (OECD TG 407 and 408) for these tests specify the dose levels and number of animals per dose but do not specify the strain of animals which should be used. In practice, almost all the tests are done using genetically undefined "albino" rats or mice in which the genetic variation, a major cause of inter-individual and strain variability, is unknown and uncontrolled. This chapter suggests that a better strategy would be to use small numbers of animals of several genetically defined strains of mice or rats instead of the undefined animals used at present. Inbred strains are more stable providing more repeatable data than outbred stocks. Importantly their greater phenotypic uniformity should lead to more powerful and repeatable tests. Any observed strain differences would indicate genetic variation in response to the test substance, providing key data. We suggest that the FDA and other regulators and funding organizations should support research to evaluate this alternative. PMID:27150081

  4. Validation of the Drug Abuse Screening Test (DAST-10): A study on illicit drug use among Chinese pregnant women

    PubMed Central

    Lam, Lap Po; Leung, Wing Cheong; Ip, Patrick; Chow, Chun Bong; Chan, Mei Fung; Ng, Judy Wai Ying; Sing, Chu; Lam, Ying Hoo; Mak, Wing Lai Tony; Chow, Kam Ming; Chin, Robert Kien Howe

    2015-01-01

    We assessed the Chinese version of the Drug Abuse Screening Test (DAST-10) for identifying illicit drug use during pregnancy among Chinese population. Chinese pregnant women attending their first antenatal visit or their first unbooked visit to the maternity ward were recruited during a 4-month study period in 2011. The participants completed self-administered questionnaires on demographic information, a single question on illicit drug use during pregnancy and the DAST-10. Urine samples screened positive by the urine Point-of-Care Test were confirmed by gas chromatography-mass spectrometry. DAST-10 performance was compared with three different gold standards: urinalysis, self-reported drug use, and evidence of drug use by urinalysis or self-report. 1214 Chinese pregnant women participated in the study and 1085 complete DAST-10 forms were collected. Women who had used illicit drugs had significantly different DAST-10 scores than those who had not. The sensitivity of DAST-10 for identify illicit drug use in pregnant women ranged from 79.2% to 33.3% and specificity ranged from 67.7% to 99.7% using cut-off scores from ≥1 to ≥3. The ~80% sensitivity of DAST-10 using a cut-off score of ≥1 should be sufficient for screening of illicit drug use in Chinese pregnant women, but validation tests for drug use are needed. PMID:26091290

  5. Validation of the Drug Abuse Screening Test (DAST-10): A study on illicit drug use among Chinese pregnant women.

    PubMed

    Lam, Lap Po; Leung, Wing Cheong; Ip, Patrick; Chow, Chun Bong; Chan, Mei Fung; Ng, Judy Wai Ying; Sing, Chu; Lam, Ying Hoo; Mak, Wing Lai Tony; Chow, Kam Ming; Chin, Robert Kien Howe

    2015-01-01

    We assessed the Chinese version of the Drug Abuse Screening Test (DAST-10) for identifying illicit drug use during pregnancy among Chinese population. Chinese pregnant women attending their first antenatal visit or their first unbooked visit to the maternity ward were recruited during a 4-month study period in 2011. The participants completed self-administered questionnaires on demographic information, a single question on illicit drug use during pregnancy and the DAST-10. Urine samples screened positive by the urine Point-of-Care Test were confirmed by gas chromatography-mass spectrometry. DAST-10 performance was compared with three different gold standards: urinalysis, self-reported drug use, and evidence of drug use by urinalysis or self-report. 1214 Chinese pregnant women participated in the study and 1085 complete DAST-10 forms were collected. Women who had used illicit drugs had significantly different DAST-10 scores than those who had not. The sensitivity of DAST-10 for identify illicit drug use in pregnant women ranged from 79.2% to 33.3% and specificity ranged from 67.7% to 99.7% using cut-off scores from ≥ 1 to ≥ 3. The ~ 80% sensitivity of DAST-10 using a cut-off score of ≥ 1 should be sufficient for screening of illicit drug use in Chinese pregnant women, but validation tests for drug use are needed. PMID:26091290

  6. Text of American Council's Draft Guidelines on Testing Athletes for Drugs.

    ERIC Educational Resources Information Center

    Chronicle of Higher Education, 1986

    1986-01-01

    The text of the American Council on Education's draft of proposed guidelines for drug testing of college athletes is provided. The purpose of programs for testing intercollegiate athletes for use of drugs, it is suggested, should be to prevent use of performance-enhancing drugs that undermine the integrity of athletic competition. (MLW) PUBTYPE-055

  7. 21 CFR 310.103 - New drug substances intended for hypersensitivity testing.

    Code of Federal Regulations, 2011 CFR

    2011-04-01

    ... new drug substance, as defined in § 310.3(g), for such purpose if all of the following conditions are... testing is not promoted by the manufacturer or distributor. (2) The new drug substance requested is an... of the practice of medicine and is used solely for such patch testing. (5) The new drug substance...

  8. 21 CFR 310.103 - New drug substances intended for hypersensitivity testing.

    Code of Federal Regulations, 2010 CFR

    2010-04-01

    ... new drug substance, as defined in § 310.3(g), for such purpose if all of the following conditions are... testing is not promoted by the manufacturer or distributor. (2) The new drug substance requested is an... of the practice of medicine and is used solely for such patch testing. (5) The new drug substance...

  9. "Vernonia v. Acton": Should Schools Conduct Random Drug Tests of Student Athletes?

    ERIC Educational Resources Information Center

    Mahon, J. Patrick

    1995-01-01

    In June 1995, the U.S. Supreme Court upheld the Vernonia (Oregon) School District's right to conduct random drug tests of its student athletes. The court balanced a seventh grader's privacy interest with the state's interest in curbing drug abuse among student athletes. Before adopting drug-testing policies, school boards should assess the local…

  10. 49 CFR 40.31 - Who may collect urine specimens for DOT drug testing?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... 49 Transportation 1 2011-10-01 2011-10-01 false Who may collect urine specimens for DOT drug... TRANSPORTATION WORKPLACE DRUG AND ALCOHOL TESTING PROGRAMS Urine Collection Personnel § 40.31 Who may collect urine specimens for DOT drug testing? (a) Collectors meeting the requirements of this subpart are...

  11. 78 FR 2675 - Mandatory Guidelines for Federal Workplace Drug Testing Programs

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-01-14

    ... HUMAN SERVICES Mandatory Guidelines for Federal Workplace Drug Testing Programs AGENCY: Substance Abuse... the Department of Health and Human Services (HHS) Mandatory Guidelines for Federal Workplace Drug... Federal employee drug testing results that seek approval by the Secretary must submit their...

  12. 76 FR 74063 - Mandatory Guidelines for Federal Workplace Drug Testing Programs

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-11-30

    ... HUMAN SERVICES Mandatory Guidelines for Federal Workplace Drug Testing Programs AGENCY: Substance Abuse... the Department of Health and Human Services (HHS) Mandatory Guidelines for Federal Workplace Drug... Federal employee drug testing results that seek approval by the Secretary must submit their...

  13. 10 CFR 26.139 - Reporting initial validity and drug test results.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 1 2010-01-01 2010-01-01 false Reporting initial validity and drug test results. 26.139 Section 26.139 Energy NUCLEAR REGULATORY COMMISSION FITNESS FOR DUTY PROGRAMS Licensee Testing Facilities § 26.139 Reporting initial validity and drug test results. (a) The licensee testing facility...

  14. 10 CFR 26.139 - Reporting initial validity and drug test results.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 1 2013-01-01 2013-01-01 false Reporting initial validity and drug test results. 26.139 Section 26.139 Energy NUCLEAR REGULATORY COMMISSION FITNESS FOR DUTY PROGRAMS Licensee Testing Facilities § 26.139 Reporting initial validity and drug test results. (a) The licensee testing facility...

  15. 10 CFR 26.139 - Reporting initial validity and drug test results.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 1 2012-01-01 2012-01-01 false Reporting initial validity and drug test results. 26.139 Section 26.139 Energy NUCLEAR REGULATORY COMMISSION FITNESS FOR DUTY PROGRAMS Licensee Testing Facilities § 26.139 Reporting initial validity and drug test results. (a) The licensee testing facility...

  16. 10 CFR 26.139 - Reporting initial validity and drug test results.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 1 2011-01-01 2011-01-01 false Reporting initial validity and drug test results. 26.139 Section 26.139 Energy NUCLEAR REGULATORY COMMISSION FITNESS FOR DUTY PROGRAMS Licensee Testing Facilities § 26.139 Reporting initial validity and drug test results. (a) The licensee testing facility...

  17. 10 CFR 26.139 - Reporting initial validity and drug test results.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 1 2014-01-01 2014-01-01 false Reporting initial validity and drug test results. 26.139 Section 26.139 Energy NUCLEAR REGULATORY COMMISSION FITNESS FOR DUTY PROGRAMS Licensee Testing Facilities § 26.139 Reporting initial validity and drug test results. (a) The licensee testing facility...

  18. 49 CFR 219.903 - Retention of drug testing records.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... by part 40 of this title, each railroad must maintain drug abuse prevention program records in a.... (4) Records related to employee training: (i) Materials on drug abuse awareness, including a copy of the railroad's policy on drug abuse. (ii) Documentation of compliance with the requirements of §...

  19. Concordance of self-reported drug use and saliva drug tests in a sample of emergency department patients

    PubMed Central

    Macdonald, Scott; Cherpitel, Cheryl J.; Stockwell, Tim; Martin, Gina; Ishiguro, Sonya; Vallance, Kate; Brubacher, Jeff

    2013-01-01

    The purpose of this study was to assess the concordance of self-reports of cannabis, cocaine and amphetamines, and the utility of these, with a saliva point of collection drug test, the DrugWipe 5+, in an emergency department (ED) setting. Methods A random sample of people admitted to either of two emergency departments at hospitals in British Columbia, Canada were asked to participate in an interview on their substance use and provide a saliva test for detection of drugs. Analyses Concordance of self-reports and drug tests were calculated. Prior DrugWipe 5+ sensitivity and specificity estimates were compared against a gold standard of mass spectrometry and chromatography (MS/GC). This was used as a basis to assess the truthfulness of self-reports for each drug. Results Of the 1584 patients approached 1190 agreed to participate, a response rate of 75.1%. For cannabis, among those who acknowledged use only 21.1% had a positive test and 2.1% of those who reported no use had a positive test. For cocaine and amphetamines respectively, 50.0% and 57.1% tested positive among those reporting use, while 2.1% and 1.3%, respectively reported no use and tested positive. Self-reports of cannabis and amphetamines use appear more truthful than self-reports of cocaine use. PMID:25104914

  20. 49 CFR 40.13 - How do DOT drug and alcohol tests relate to non-DOT tests?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... drugs, and a laboratory is prohibited from making a DOT urine specimen available for a DNA test or other... a blood or urine specimen collected by the employee's physician or a DNA test result purporting...

  1. 49 CFR 40.13 - How do DOT drug and alcohol tests relate to non-DOT tests?

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... drugs, and a laboratory is prohibited from making a DOT urine specimen available for a DNA test or other... a blood or urine specimen collected by the employee's physician or a DNA test result purporting...

  2. 49 CFR 40.13 - How do DOT drug and alcohol tests relate to non-DOT tests?

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... drugs, and a laboratory is prohibited from making a DOT urine specimen available for a DNA test or other... a blood or urine specimen collected by the employee's physician or a DNA test result purporting...

  3. 49 CFR 40.13 - How do DOT drug and alcohol tests relate to non-DOT tests?

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... drugs, and a laboratory is prohibited from making a DOT urine specimen available for a DNA test or other... a blood or urine specimen collected by the employee's physician or a DNA test result purporting...

  4. 49 CFR 40.13 - How do DOT drug and alcohol tests relate to non-DOT tests?

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... drugs, and a laboratory is prohibited from making a DOT urine specimen available for a DNA test or other... a blood or urine specimen collected by the employee's physician or a DNA test result purporting...

  5. Test-Retest Stability and Concurrent Validity of Two Reading Tests with a Drug-Abusing Population.

    ERIC Educational Resources Information Center

    Johnson, Mark E.; Fisher, Dennis G.; Rhodes, Fen; Booth, Robert

    1996-01-01

    The Wide Range Achievement Test-Revised and the Woodcock Reading Mastery Tests-Revised were administered twice to 269 current drug abusers over an average time interval of 204.2 days. Overall, the study demonstrates that the two instruments have strong psychometric properties and that results from current drug abusers are reliable. (SLD)

  6. Field testing of the Alere DDS2 Mobile Test System for drugs in oral fluid.

    PubMed

    Moore, Christine; Kelley-Baker, Tara; Lacey, John

    2013-06-01

    A preliminary field evaluation of a second-generation handheld oral fluid testing device, the Alere DDS2 Mobile Test System (DDS2), is described. As part of a larger study, drivers were randomly stopped at various locations across California (in 2012) and asked to submit voluntarily to a questionnaire regarding their drug and alcohol use, a breath alcohol test and collection of oral fluid with the Quantisal device. The Quantisal-collected oral fluid samples were sent for laboratory-based analyses. At one location, 50 drivers were asked to submit an additional oral fluid sample using the DDS2 collection device; these samples were analyzed by using the DDS2 mobile test system. Thirty-eight donors (76%) provided specimens that were successfully run on the mobile system; in 12 cases (24%), the device failed to provide a valid result. Thirty-two of the 38 collected samples were negative for all drugs; five were positive for tetrahydrocannabinol and one was positive for methamphetamine using the mobile device. These results corresponded exactly with the laboratory-based results from the Quantisal oral fluid collection. PMID:23558436

  7. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors

    PubMed Central

    Jonas, Oliver; Landry, Heather M.; Fuller, Jason E.; Santini, John T.; Baselga, Jose; Tepper, Robert I.; Cima, Michael J.; Langer, Robert

    2016-01-01

    Current anticancer chemotherapy relies on a limited set of in vitro or indirect prognostic markers of tumor response to available drugs. A more accurate analysis of drug sensitivity would involve studying tumor response in vivo. To this end, we have developed an implantable device that can perform drug sensitivity testing of several anticancer agents simultaneously inside the living tumor. The device contained reservoirs that released microdoses of single agents or drug combinations into spatially distinct regions of the tumor. The local drug concentrations were chosen to be representative of concentrations achieved during systemic treatment. Local efficacy and drug concentration profiles were evaluated for each drug or drug combination on the device, and the local efficacy was confirmed to be a predictor of systemic efficacy in vivo for multiple drugs and tumor models. Currently, up to 16 individual drugs or combinations can be assessed independently, without systemic drug exposure, through minimally invasive biopsy of a small region of a single tumor. This assay takes into consideration physiologic effects that contribute to drug response by allowing drugs to interact with the living tumor in its native microenvironment. Because these effects are crucial to predicting drug response, we envision that these devices will help identify optimal drug therapy before systemic treatment is initiated and could improve drug response prediction beyond the biomarkers and in vitro and ex vivo studies used today. These devices may also be used in clinical drug development to safely gather efficacy data on new compounds before pharmacological optimization. PMID:25904741

  8. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors.

    PubMed

    Jonas, Oliver; Landry, Heather M; Fuller, Jason E; Santini, John T; Baselga, Jose; Tepper, Robert I; Cima, Michael J; Langer, Robert

    2015-04-22

    Current anticancer chemotherapy relies on a limited set of in vitro or indirect prognostic markers of tumor response to available drugs. A more accurate analysis of drug sensitivity would involve studying tumor response in vivo. To this end, we have developed an implantable device that can perform drug sensitivity testing of several anticancer agents simultaneously inside the living tumor. The device contained reservoirs that released microdoses of single agents or drug combinations into spatially distinct regions of the tumor. The local drug concentrations were chosen to be representative of concentrations achieved during systemic treatment. Local efficacy and drug concentration profiles were evaluated for each drug or drug combination on the device, and the local efficacy was confirmed to be a predictor of systemic efficacy in vivo for multiple drugs and tumor models. Currently, up to 16 individual drugs or combinations can be assessed independently, without systemic drug exposure, through minimally invasive biopsy of a small region of a single tumor. This assay takes into consideration physiologic effects that contribute to drug response by allowing drugs to interact with the living tumor in its native microenvironment. Because these effects are crucial to predicting drug response, we envision that these devices will help identify optimal drug therapy before systemic treatment is initiated and could improve drug response prediction beyond the biomarkers and in vitro and ex vivo studies used today. These devices may also be used in clinical drug development to safely gather efficacy data on new compounds before pharmacological optimization. PMID:25904741

  9. Juvenile animal testing in drug development--is it useful?

    PubMed

    Baldrick, Paul

    2010-01-01

    In pharmaceutical drug development, there has been increased interest in the need to perform juvenile animal studies to support the safety of use of new medicines in the pediatric population. Although such studies are not new, the increased interest has been "formalized" in recent regulatory guidelines. As a result, companies are now performing many more studies in juvenile animals, even when there is a lack of robust knowledge of cross-species functional and kinetic differences among juveniles that means extrapolation of any toxicology study finding to an immature human may not be easy or even relevant, especially if performed in the wrong species at the wrong time. It will be shown by presentation of some basic considerations needed in order to perform such testing, that juvenile animal studies are indeed feasible. However, it will also be highlighted that (based on available knowledge) there are currently not enough clear-cut examples to answer the question of whether juvenile animal toxicology studies to support pediatric development (by affecting the performance or design of a pediatric clinical trial or identifying a potential different-from-adult safety risk in clinical use) are truly useful or necessary. PMID:20350578

  10. 49 CFR 40.31 - Who may collect urine specimens for DOT drug testing?

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... urine specimens for DOT drug testing? (a) Collectors meeting the requirements of this subpart are the only persons authorized to collect urine specimens for DOT drug testing. (b) A collector must meet... act as the collector when that employee is tested, unless no other collector is available and you...

  11. 49 CFR 40.31 - Who may collect urine specimens for DOT drug testing?

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... urine specimens for DOT drug testing? (a) Collectors meeting the requirements of this subpart are the only persons authorized to collect urine specimens for DOT drug testing. (b) A collector must meet... act as the collector when that employee is tested, unless no other collector is available and you...

  12. 49 CFR 40.31 - Who may collect urine specimens for DOT drug testing?

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... urine specimens for DOT drug testing? (a) Collectors meeting the requirements of this subpart are the only persons authorized to collect urine specimens for DOT drug testing. (b) A collector must meet... act as the collector when that employee is tested, unless no other collector is available and you...

  13. 49 CFR 40.31 - Who may collect urine specimens for DOT drug testing?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... urine specimens for DOT drug testing? (a) Collectors meeting the requirements of this subpart are the only persons authorized to collect urine specimens for DOT drug testing. (b) A collector must meet... act as the collector when that employee is tested, unless no other collector is available and you...

  14. 49 CFR 40.123 - What are the MRO's responsibilities in the DOT drug testing program?

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... drug testing program? 40.123 Section 40.123 Transportation Office of the Secretary of Transportation... Verification Process § 40.123 What are the MRO's responsibilities in the DOT drug testing program? As an MRO... whether there is a problem that may cause a test to be cancelled (see §§ 40.199-40.203 ). As an MRO,...

  15. 10 CFR 707.11 - Drugs for which testing is performed.

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 4 2012-01-01 2012-01-01 false Drugs for which testing is performed. 707.11 Section 707.11 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.11 Drugs for which testing is performed. Where testing is performed under this part, at a...

  16. 10 CFR 707.11 - Drugs for which testing is performed.

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 4 2011-01-01 2011-01-01 false Drugs for which testing is performed. 707.11 Section 707.11 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.11 Drugs for which testing is performed. Where testing is performed under this part, at a...

  17. 10 CFR 707.11 - Drugs for which testing is performed.

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 4 2013-01-01 2013-01-01 false Drugs for which testing is performed. 707.11 Section 707.11 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.11 Drugs for which testing is performed. Where testing is performed under this part, at a...

  18. 10 CFR 707.11 - Drugs for which testing is performed.

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 4 2010-01-01 2010-01-01 false Drugs for which testing is performed. 707.11 Section 707.11 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.11 Drugs for which testing is performed. Where testing is performed under this part, at a...

  19. 10 CFR 707.11 - Drugs for which testing is performed.

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 4 2014-01-01 2014-01-01 false Drugs for which testing is performed. 707.11 Section 707.11 Energy DEPARTMENT OF ENERGY WORKPLACE SUBSTANCE ABUSE PROGRAMS AT DOE SITES Procedures § 707.11 Drugs for which testing is performed. Where testing is performed under this part, at a...

  20. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

    PubMed Central

    Pietarinen, P O; Pemovska, T; Kontro, M; Yadav, B; Mpindi, J P; Andersson, E I; Majumder, M M; Kuusanmäki, H; Koskenvesa, P; Kallioniemi, O; Wennerberg, K; Heckman, C A; Mustjoki, S; Porkka, K

    2015-01-01

    Chronic myeloid leukemia in blast crisis (CML BC) remains a challenging disease to treat despite the introduction and advances in tyrosine kinase inhibitor (TKI) therapy. In this study we set out to identify novel candidate drugs for CML BC by using an unbiased high-throughput drug testing platform. We used three CML cell lines representing different types of CML blast phases (K562, EM-2 and MOLM-1) and primary leukemic cells from three CML BC patients. Profiling of drug responses was performed with a drug sensitivity and resistance testing platform comprising 295 anticancer agents. Overall, drug sensitivity scores and the drug response profiles of cell line and primary cell samples correlated well and were distinct from other types of leukemia samples. The cell lines were highly sensitive to TKIs and the clinically TKI-resistant patient samples were also resistant ex vivo. Comparison of cell line and patient sample data identified new candidate drugs for CML BC, such as vascular endothelial growth factor receptor and nicotinamide phosphoribosyltransferase inhibitors. Our results indicate that these drugs in particular warrant further evaluation by analyzing a larger set of primary patient samples. The results also pave way for designing rational combination therapies. PMID:25933373

  1. 49 CFR 199.109 - Review of drug testing results.

    Code of Federal Regulations, 2014 CFR

    2014-10-01

    ... MATERIALS SAFETY ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL... person under contract to provide treatment for drug problems on behalf of the operator; (3) The sole source of therapeutically appropriate treatment under the employee's health insurance program; or (4)...

  2. 49 CFR 199.109 - Review of drug testing results.

    Code of Federal Regulations, 2011 CFR

    2011-10-01

    ... MATERIALS SAFETY ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL... person under contract to provide treatment for drug problems on behalf of the operator; (3) The sole source of therapeutically appropriate treatment under the employee's health insurance program; or (4)...

  3. 49 CFR 199.109 - Review of drug testing results.

    Code of Federal Regulations, 2012 CFR

    2012-10-01

    ... MATERIALS SAFETY ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL... person under contract to provide treatment for drug problems on behalf of the operator; (3) The sole source of therapeutically appropriate treatment under the employee's health insurance program; or (4)...

  4. 49 CFR 199.109 - Review of drug testing results.

    Code of Federal Regulations, 2013 CFR

    2013-10-01

    ... MATERIALS SAFETY ADMINISTRATION, DEPARTMENT OF TRANSPORTATION (CONTINUED) PIPELINE SAFETY DRUG AND ALCOHOL... person under contract to provide treatment for drug problems on behalf of the operator; (3) The sole source of therapeutically appropriate treatment under the employee's health insurance program; or (4)...

  5. [Acute toxicity testing (LD50) of Chinese mineral drugs].

    PubMed

    Yue, W; Liu, W H; Wang, L F; Fu, S X; Li, Y S; Kong, Z K; Tang, Z X; Chen, Z L

    1989-02-01

    Acute toxicity and LD50 of 62 mineral drugs were determined by ig, ip or iv in mice, in order to provide some guidelines for safety in clinical use, as well as for pharmacological and toxicological studies. In the present investigation, the difference in the acute toxicity and LD50 between raw drugs and medicines prepared by roasting is explained. PMID:2506896

  6. Drug testing in the patient: toward personalized cancer treatment.

    PubMed

    Coombes, R Charles

    2015-04-22

    Two different devices show that delivery of cancer drugs directly into tumors in vivo can indicate cancer sensitivity; if implemented in clinical practice, these devices have the potential to reduce indiscriminate drug use, to improve survival, and to reduce unnecessary adverse effects (Jonas et al. and Klinghoffer et al., this issue). PMID:25904739

  7. Urine Testing for Drugs of Abuse. NIDA Research Monograph Series 73.

    ERIC Educational Resources Information Center

    Hawks, Richard L., Ed.; Chiang, C. Nora, Ed.

    In the past 5 years, a growing concern over the use of illicit drugs in the workplace has led to an interest in urinalysis as a way to detect and deter drug use. This monograph provides information that will assist those involved in the planning or implementation of drug testing programs in making informed choices. Articles include: (1)…

  8. 49 CFR 219.602 - FRA Administrator's determination of random drug testing rate.

    Code of Federal Regulations, 2010 CFR

    2010-10-01

    ... 49 Transportation 4 2010-10-01 2010-10-01 false FRA Administrator's determination of random drug... (Continued) FEDERAL RAILROAD ADMINISTRATION, DEPARTMENT OF TRANSPORTATION CONTROL OF ALCOHOL AND DRUG USE Random Alcohol and Drug Testing Programs § 219.602 FRA Administrator's determination of random...

  9. 78 FR 71036 - Pipeline Safety: Random Drug Testing Rate; Contractor Management Information System Reporting...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-11-27

    ... published an Advisory Bulletin (75 FR 2926) implementing the annual collection of contractor MIS drug and...; Contractor Management Information System Reporting; and Obtaining Drug and Alcohol Management Information.... Operators are reminded that drug and alcohol testing information must be submitted for...

  10. The Interactive Seminar: An Educational Approach for Voluntary HIV Testing in a Drug Dependence Treatment Unit.

    ERIC Educational Resources Information Center

    Sedhom, Laila; And Others

    1994-01-01

    A survey of 118 male patients in a drug dependence treatment unit before and after an interactive seminar with a nonjudgmental professional showed that seminar participants, especially intravenous drug users, had higher rates of voluntary HIV testing than nonparticipants. Drug users who completed detoxification and attended the seminar also had…